<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010222766
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EXFORGE HCT 10MG/320MG/25MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN,HYDROCHLOROTHIAZIDE,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        320,25,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        111.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS FARMA S.P.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS FARMA S.P.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        C09DA03
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Exforge HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide. All of these substances help to control high blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amlodipine belongs to a group of substances called &ldquo;calcium channel blockers&rdquo;. Amlodipine stops calcium from moving into the blood vessel wall, which stops the blood vessels from tightening.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Valsartan belongs to a group of substances called &ldquo;angiotensin-II receptor antagonists&rdquo;. Angiotensin II is produced by the body and makes the blood vessels tighten, thus increasing the blood pressure. Valsartan works by blocking the effect of angiotensin II.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrochlorothiazide belongs to a group of substances called &ldquo;thiazide diuretics&rdquo;. Hydrochlorothiazide increases urine output, which also lowers blood pressure.</p><p>As a result of all three mechanisms, the blood vessels relax and blood pressure is lowered.</p><p>&nbsp;</p><p>Exforge HCT is used to treat high blood pressure in adult patients whose blood pressure is already controlled while taking amlodipine, valsartan and hydrochlorothiazide and who may benefit from taking one tablet containing all three substances.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Exforge HCT</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3&nbsp;months pregnant. (It is also recommended to avoid Exforge HCT in early pregnancy &ndash; see Pregnancy section.)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to amlodipine or to any other calcium channel blockers, valsartan, hydrochlorothiazide, sulphonamide-derived medicines (medicines used to treat chest or urinary infections), or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>If you think you may be allergic, do not take Exforge HCT and talk to your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver disease, destruction of the small bile ducts within the liver (biliary cirrhosis) leading to the build up of bile in the liver (cholestasis).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>severe</strong> kidney problems or if you are having dialysis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are unable to produce urine (anuria).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the level of potassium or sodium in your blood is too low despite treatment to increase the potassium or sodium levels in your blood.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the level of calcium in your blood is too high despite treatment to reduce the calcium levels in your blood.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have gout (uric acid crystals in the joints).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe low blood pressure (hypotension).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have narrowing of the aortic valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from heart failure after a heart attack.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p><strong>If any of the above applies to you, do not take Exforge HCT and talk to your doctor</strong>.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Exforge HCT</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a low level of potassium or magnesium in your blood (with or without symptoms such as muscle weakness, muscle spasms, abnormal heart rhythm).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a low level of sodium in your blood (with or without symptoms such as tiredness, confusion, muscle twitching, convulsions).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a high level of calcium in your blood (with or without symptoms such as nausea, vomiting, constipation, stomach pain, frequent urination, thirst, muscle weakness and twitching).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems, have had a kidney transplant or if you had been told that you have a narrowing of your kidney arteries.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or have had heart failure or coronary artery<u> </u>disease, particularly if you are prescribed the maximum dose of Exforge HCT (10&nbsp;mg/320&nbsp;mg/25&nbsp;mg).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have experienced a heart attack. Follow your doctor&rsquo;s instructions for the starting dose carefully. Your doctor may also check your kidney function.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your doctor has told you that you have a narrowing of the valves in your heart (called &ldquo;aortic or mitral stenosis&rdquo;) or that the thickness of your heart muscle is abnormally increased (called &ldquo;obstructive hypertrophic cardiomyopathy&rdquo;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from aldosteronism. This is a disease in which the adrenal glands make too much of the hormone aldosterone If this applies to you, the use of Exforge HCT is not recommended.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from a disease called systemic lupus erythematosus (also called &ldquo;lupus&rdquo; or &ldquo;SLE&rdquo;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes (high level of sugar in your blood).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have high levels of cholesterol or triglycerides in your blood.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience skin reactions such as rash after sun exposure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you had an allergic reaction to other high blood pressure medicines or diuretics (a type of medicine also known as &ldquo;water tablets&rdquo;), especially if you suffer from asthma and allergies</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have been sick (vomiting or diarrhoea).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have experienced swelling, particularly of the face and throat, while taking other medicines (including angiotensin converting enzyme inhibitors). If you get these symptoms, stop taking Exforge HCT and contact your doctor straight away. You should never take Exforge HCT again.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience dizziness and/or fainting during treatment with Exforge HCT, tell your doctor as soon as possible.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience a decrease in vision or eye pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to a week of taking Exforge HCT. This can lead to permanent vision impairment, if not treated.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines used to treat high blood pressure:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an ACE inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had skin cancer or if you develop an unexpected skin lesion during the treatment. Treatment with hydrochlorothiazide, particularly long term use with high doses, may increase the risk of some types of skin and lip cancer (non-melanoma skin cancer). Protect your skin from sun exposure and UV rays while taking Exforge HCT.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experienced breathing or lung problems (including inflammation or fluid in the lungs) following hydrochlorothiazide intake in the past. If you develop any severe shortness of breath or difficulty breathing after taking Exforge HCT, seek medical attention immediately.</p><p>&nbsp;</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>&nbsp;</p><p>See also information under the heading &ldquo;Do not take Exforge HCT&rdquo;.</p><p>&nbsp;</p><p><strong>If any of these apply to you, talk to your doctor.</strong></p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>The use of Exforge HCT in children and adolescents under 18&nbsp;years of age is not recommended.</p><p>&nbsp;</p><p><strong>Elderly people (age 65&nbsp;years and older)</strong></p><p>Exforge HCT can be used by people aged 65&nbsp;years and over at the same dose as for other adults and in the same way as they have already taken the three substances called amlodipine, valsartan and hydrochlorothiazide. Elderly patients, particularly those taking the maximum dose of Exforge HCT (10&nbsp;mg/320&nbsp;mg/25&nbsp;mg), should have their blood pressure checked regularly.</p><p>&nbsp;</p><p><strong>Other medicines and Exforge HCT</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor may need to change your dose and/or to take other precautions. In some cases you may have to stop using one of the medicines. This is especially important if you are using any of the medicines listed below:</p><p>&nbsp;</p><p><u>Do not take together with:</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lithium (a medicine used to treat some types of depression);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines or substances that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACE inhibitors or aliskiren (see also information under the headings &ldquo;Do not take Exforge HCT&rdquo; and &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p><u>Caution should be used with:</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alcohol, sleeping pills and anaesthetics (medicines allowing patients to undergo surgery and other procedures);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amantadine (anti-Parkinson therapy, also used to treat or prevent certain illnesses caused by viruses);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticholinergic agents (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson&#39;s disease and as an aid to anaesthesia);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticonvulsant medicines and mood-stabilising medicines used to treat epilepsy and bipolar disorder (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cholestyramine, colestipol or other resins (substances used mainly to treat high levels of lipids in the blood);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; simvastatin (a medicine used to control high cholesterol levels);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin (a medicine used in transplantation to prevent organ rejection or for other conditions, e.g: rheumatoid arthritis or atopic dermatitis);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cytotoxic medicines (used to treat cancer), such as methotrexate or cyclophosphamide;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin or other digitalis glycosides (medicines used to treat heart problems);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; verapamil, diltiazem (heart medicines);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; iodine contrast media (agents used for imaging examinations);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for the treatment of diabetes (oral agents such as metformin or insulins);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for the treatment of gout, such as allopurinol;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that may increase blood sugar levels (beta blockers, diazoxide);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that may induce <em>&ldquo;torsades de pointes&rdquo;</em> (irregular heart beat), such as antiarrhythmics (medicines used to treat heart problems) and some antipsychotics;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that may reduce the amount of sodium in your blood, such as antidepressants, antipsychotics, antiepileptics;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that may reduce the amount of potassium in your blood, such as diuretics (water tablets), corticosteroids, laxatives, amphotericin or penicillin G;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to increase blood pressure such as adrenaline or noradrenaline;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used for HIV/AIDS (e.g. ritonavir, indinavir, nelfinavir);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat fungal infections (e.g. ketoconazole, itraconazole);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used for oesophageal ulceration and inflammation (carbenoxolone);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to relieve pain or inflammation, especially non-steroidal anti-inflammatory agents (NSAIDs), including selective cyclooxygenase-2 inhibitors (Cox-2 inhibitors);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle relaxants (medicines to relax the muscles which are used during operations);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nitroglycerin and other nitrates, or other substances called &ldquo;vasodilators&rdquo;;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines to treat high blood pressure, including methyldopa;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (used, for example, to treat tuberculosis), erythromycin, clarithromycin (antibiotics);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dantrolene (infusion for severe body temperature abnormalities);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tacrolimus (used to control your body&rsquo;s immune response, enabling your body to accept the transplanted organ);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vitamin D and calcium salts.</p><p>&nbsp;</p><p><strong>Exforge HCT with food, drink and alcohol</strong></p><p>Grapefruit and grapefruit juice should not be consumed by people who are prescribed Exforge HCT. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Exforge HCT. Talk to your doctor before drinking alcohol. Alcohol may make your blood pressure fall too much and/or increase the possibility of dizziness or fainting.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p><u>Pregnancy</u></p><p>You must <strong>tell your doctor</strong> if you think you are (<u>or might become</u>) pregnant. Your doctor will normally advise you to stop taking Exforge HCT before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Exforge HCT. Exforge HCT is not recommended in early pregnancy and must not be taken when more than 3&nbsp;months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><strong>Tell your doctor</strong> if you are breast-feeding <u>or about to start breast-feeding</u>. Amlodipine has been shown to pass into breast milk in small amounts. Exforge HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>This medicine may make you feel dizzy, drowsy, nauseous or have a headache. If you experience these symptoms, do not drive or use tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. This will help you get the best results and lower the risk of side effects.</p><p>&nbsp;</p><p>The usual dose of Exforge HCT is <strong>one tablet</strong> per day.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is best to take the tablet at the same time each day. Morning is the best time.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet whole with a glass of water.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take Exforge HCT with or without food. Do not take Exforge HCT with grapefruit or grapefruit juice.</p><p>&nbsp;</p><p>Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.</p><p>&nbsp;</p><p>Do not exceed the prescribed dose.</p><p>&nbsp;</p><p><strong>If you take more Exforge HCT than you should</strong></p><p>If you have accidentally taken too many Exforge HCT tablets, talk to a doctor immediately. You may require medical attention. Excess fluid may accumulate in your lungs (pulmonary oedema) causing shortness of breath that may develop up to 24-48&nbsp;hours after intake.</p><p>&nbsp;</p><p><strong>If you forget to take Exforge HCT</strong></p><p>If you forget to take a dose of this medicine, take it as soon as you remember and then take the next dose at its usual time. If it is almost time for your next dose you should simply take the next tablet at the usual time. <strong>Do not </strong>take a double dose (two tablets at once) to make up for a forgotten tablet.</p><p>&nbsp;</p><p><strong>If you stop taking Exforge HCT</strong></p><p>Stopping your treatment with Exforge HCT may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.</p><p>&nbsp;</p><p><strong>Always take this medicine, even if you are feeling well</strong></p><p>People who have high blood pressure often do not notice any signs of the problem. Many feel normal. It is very important that you take this medicine exactly as your doctor tells you to get the best results and reduce the risk of side effects. Keep your appointments with the doctor even if you are feeling well.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>As for any combination containing three active substances, side effects associated with each individual component cannot be excluded. The side effects reported with Exforge HCT or one of its three active substances (amlodipine, valsartan and hydrochlorothiazide) are listed below and may occur with the use of Exforge HCT.</p><p>&nbsp;</p><p><strong>Some side effects can be serious and need immediate medical attention.</strong></p><p><strong>Consult a doctor immediately if you experience any of the following serious side effects after taking this medicine:</strong></p><p><em>Common (may affect up to 1 in 10&nbsp;people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (feeling of faintness, light-headedness, sudden loss of consciousness)</p><p>&nbsp;</p><p><em>Uncommon (may affect up to 1 in 100&nbsp;people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severely decreased urine output (decreased kidney function)</p><p>&nbsp;</p><p><em>Rare (may affect up to 1 in 1,000&nbsp;people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spontaneous bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver disorder</p><p>&nbsp;</p><p><em>Very rare (may affect up to 1 in 10,000&nbsp;people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden wheeziness, chest pain, shortness of breath or difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of eyelids, face or lips</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the tongue and throat which causes great difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis) or other allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute respiratory distress (signs include severe shortness of breath, fever, weakness, and confusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed pancreas, which may cause severe abdominal and back pain accompanied with feeling of being very unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness, bruising, fever and frequent infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness</p><p>&nbsp;</p><p><strong>Other side effects may include:</strong></p><p><em>Very </em><em>common (may affect more than 1 in 10&nbsp;people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of potassium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of lipids in the blood</p><p>&nbsp;</p><p><em>C</em><em>ommon (may affect up to 1 in 10&nbsp;people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations (awareness of your heart beat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ankle swelling (oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach discomfort after meal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; frequent urination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of uric acid in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of magnesium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of sodium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, fainting on standing up</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea and vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy rash and other types of rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to achieve or maintain erection</p><p>&nbsp;</p><p><em>Uncommon (may affect up to 1 in 100&nbsp;people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spinning sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of urea nitrogen, creatinine and uric acid in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of calcium, fat or sodium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease of potassium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breath odour</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight increase</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbed sense of taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle cramps/weakness/pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in extremity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to either stand or walk in a normal manner</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal coordination</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness on standing up or after exercising</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of energy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep disturbances</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neuropathy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden, temporary loss of consciousness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure on standing up</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; throat irritation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, reddening and pain along a vein</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reddening</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trembling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mood changes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleeplessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; taste abnormalities</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of pain sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual disturbances</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual impairment</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sneezing/runny nose caused by inflammation of the lining of the nose (rhinitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; altered bowel habits</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin discolouration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorder in passing urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased need to urinate at night</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased number of times of passing urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discomfort or enlargement of the breasts in men</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight decrease</p><p><em>&nbsp;</em></p><p><em>Rare (may affect up to 1 in 1,000&nbsp;people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of blood platelets (sometimes with bleeding or bruising underneath the skin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sugar in the urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of sugar in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening of the diabetic metabolic state</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver disorders which can occur together with yellow skin and eyes, or dark-coloured urine (haemolytic anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sensitivity of skin to sun</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; purple skin patches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&nbsp;</p><p><em>Very rare (may affect up to 1 in 10,000&nbsp;people):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of white blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in blood platelets which may result in unusual brusing or easy bleeding (red blood cell damage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the gums</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal bloating (gastritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (hepatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver enzyme increase which may have an effect on some medical tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased muscle tension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels often with skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensitivity to light</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders combining rigidity, tremor and/or movement disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, sore throat or mouth ulcers, more frequent infections (lack or low level of white blood cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pale skin, tiredness, breathlessness, dark-coloured urine (haemolytic anaemia, abnormal breakdown of red blood cells either in the blood vessels or elsewhere in the body)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraemic alkalosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe upper stomach ache (inflammation of the pancreas)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing with fever, coughing, wheezing, breathlessness (respiratory distress, pulmonary oedema, pneumonitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; facial rash, joint pain, muscle disorder, fever (lupus erythematosus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels with symptoms such as<em> </em>rash, purplish-red spots, fever (vasculitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal necrolysis)</p><p><em>&nbsp;</em></p><p><em>Not known (frequency cannot be estimated from the available data):</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood tests for kidney function, increase of potassium in your blood, low level of red blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal red blood cell test</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of a certain type of white blood cell and blood platelet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of creatinine in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal liver function test</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severely decreased urine output</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness, bruising and frequent infections (aplastic anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in vision or pain in your eyes due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severely decreased urine output (possible signs of renal disorder or renal failure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (erythema multiforme)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (pyrexia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blistering skin (sign of a condition called dermatitis bullous)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin and lip cancer (non-melanoma skin cancer)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from moisture.</p><p>&nbsp;</p><p>Do not use any Exforge HCT pack that is damaged or shows signs of tampering.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Exforge HCT 5&nbsp;mg/160&nbsp;mg/12.5&nbsp;mg film-coated tablets</strong></p><p>The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide. Each film-coated tablet contains 5&nbsp;mg amlodipine (as amlodipine besylate), 160&nbsp;mg valsartan and 12.5&nbsp;mg hydrochlorothiazide.</p><p>&nbsp;</p><p>The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous; magnesium stearate; hypromellose (substitution type 2910 (3 mPa.s)), macrogol 4000, talc, titanium dioxide (E171).</p><p>&nbsp;</p><p><strong>Exforge HCT 10&nbsp;mg/160&nbsp;mg/12.5&nbsp;mg film-coated tablets</strong></p><p>The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide. Each film-coated tablet contains 10&nbsp;mg amlodipine (as amlodipine besylate),160&nbsp;mg valsartan, and 12.5&nbsp;mg hydrochlorothiazide.</p><p>&nbsp;</p><p>The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous; magnesium stearate; hypromellose (substitution type 2910 (3 mPa.s)), macrogol 4000, talc, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172).</p><p>&nbsp;</p><p><strong>Exforge HCT 5&nbsp;mg/160&nbsp;mg/25&nbsp;mg film-coated tablets</strong></p><p>The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide. Each film-coated tablet contains 5&nbsp;mg amlodipine (as amlodipine besylate), 160&nbsp;mg valsartan and 25&nbsp;mg hydrochlorothiazide.</p><p>&nbsp;</p><p>The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous, magnesium stearate, hypromellose (substitution type 2910 (3 mPa.s)), macrogol 4000, talc, titanium dioxide (E171), yellow iron oxide (E172).</p><p>&nbsp;</p><p><strong>Exforge HCT 10&nbsp;mg/160&nbsp;mg/25&nbsp;mg film-coated tablets</strong></p><p>The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide. Each film-coated tablet contains 10&nbsp;mg amlodipine (as amlodipine besylate), 160&nbsp;mg valsartan, and 25&nbsp;mg hydrochlorothiazide.</p><p>&nbsp;</p><p>The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous, magnesium stearate, hypromellose (substitution type 2910 (3 mPa.s)), macrogol 4000, talc, yellow iron oxide (E172).</p><p>&nbsp;</p><p><strong>Exforge HCT 10&nbsp;mg/320&nbsp;mg/25&nbsp;mg film-coated tablets</strong></p><p>The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide. Each film-coated tablet contains 10&nbsp;mg amlodipine (as amlodipine besylate), 320&nbsp;mg valsartan, and 25&nbsp;mg hydrochlorothiazide.</p><p>&nbsp;</p><p>The other ingredients are cellulose microcrystalline; crospovidone (type A); silica, colloidal anhydrous, magnesium stearate, hypromellose (substitution type 2910 (3 mPa.s)), macrogol 4000, talc, yellow iron oxide (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets are white, oval tablets with “NVR” on one side and “VCL” on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets are pale yellow, oval tablets with “NVR” on one side and “VDL” on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

Exforge HCT 5 mg/160 mg/25 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “VEL” on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

Exforge HCT 10 mg/160 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VHL” on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

Exforge HCT 10 mg/320 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VFL” on the other side. Approximate size: 19 mm (length) x 7.5 mm (width).

Exforge HCT is available in packs containing 14, 28, 30, 56, 90, 98 or 280 film-coated tablets, in multipacks of 280 tablets (comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets), and in hospital packs containing 56, 98 or 280 tablets in single perforated dose blisters.

Not all pack sizes may be available in your country.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by EMA on 01/2024

e-To report any side effect(s): 
•	Saudi Arabia: 

The National Pharmacovigilance Centre (NPC):
o SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa 

Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o Toll Free Number: 8001240078
o Phone: +966112658100 
o Fax: +966112658107
o Email: adverse.events@novartis.com  

•    Other GCC States:
-  Please contact the relevant competent authority.

f. To report any complaint(s): complaints.ksa@novartis.com 

This is a Medicament
-   Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to 
instructions is dangerous for you.
-   Follow strictly the doctor’s prescription, the method of use and the instructions of the 
pharmacist who sold the medicament.
-   The doctor and the pharmacist are the experts in medicines, their benefits and risks.
-  Do not by yourself interrupt the period of treatment prescribed for you.
-   Do not repeat the same prescription without consulting your doctor.
-   Keep all medicaments out of reach of children.
                                                              
Council of Arab Health Ministers
Union of Arab Pharmacists

g. This patient information leaflet is approved by the Saudi Food and Drug Authority

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار إكسفورج إتش سي تي أقراص على ثلاث مواد تُسمى أملوديبين وفالسارتان وهيدروكلوروثيازيد. تُساعد كل هذه المواد في السيطرة على ارتفاع ضغط الدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي أملوديبين إلى مجموعة من المواد التي تُسمى &quot;حاصرات قنوات الكالسيوم&quot;. يعمل أملوديبين على إيقاف الكالسيوم من الانتقال إلى جدار الأوعية الدَّموية، الذي يمنع الأوعية الدَّموية من التَّضيق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي فالسارتان إلى مجموعة من المواد التي تُسمى &quot;مناهضات مستقبلات الأنجيوتنسين-2&quot;. يقوم الجسم بإنتاج أنجيوتنسين-2 ويسبب ضيق الأوعية الدَّموية؛ ولذا يزيد من ضغط الدَّم. يعمل فالسارتان عن طريق منع تأثير الأنجيوتنسين-2.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي هيدروكلوروثيازيد إلى مجموعة من المواد التي تُسمى &quot;مُدِرات البول الثيازيدية&quot;. يؤدي الهيدروكلوروثيازيد إلى زيادة إخراج البول، الأمر الذي يخفض أيضًا ضغط الدَّم.</p><p dir="RTL">نتيجة للآليات الثلاث للعمل، تسترخي الأوعية الدَّموية وينخفض ضغط الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار إكسفورج إتش سي تي لعلاج ارتفاع ضغط الدَّم في المرضى من البالغين ممن يجرى التحكم بالفعل في ضغط الدَّم لديهم خلال تناولهم أملوديبين وفالسارتان وهيدروكلوروثيازيد والذين قد يستفيدون من تناوُل قرص واحد يحتوي على المواد الثلاثة جميعها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول عقار إكسفورج</strong><strong>&nbsp;</strong><strong>إتش سي تي في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تجاوز حملكِ الشهر الثالث. (من الأفضل أيضًا تجنُّب تناوُل عقار إكسفورج إتش سي تي في مراحل الحمل المبكرة - انظري قسم: &quot;الحمل&quot;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية تجاه أملوديبين أو أي من حاصرات قنوات الكالسيوم الأخرى، أو فالسارتان، هيدروكلوروثيازيد، أو أيَّة أدوية مشتقة من السلفوناميد (الأدوية التي تُستَخدَم لعلاج عدوى الصدر أو الجهاز البولي)، أو أي من المكونات الأخرى الموجودة بهذا الدَّواء (المُدرَجة في قسم 6).</p><p dir="RTL">إذا كنت تعتقد أنك قد تكون لديك حساسية، فلا تتناول عقار إكسفورج إتش سي تي،<strong> </strong>وتحدَّث إلى طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مرض بالكبد، تلف بالقنوات الصفراوية الصغيرة داخل الكبد (تليُّف القنوات المرارية) يؤدي إلى تراكم العصارة الصفراوية في الكبد (الركود الصفراوي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مشاكل <strong>شديدة </strong>بالكُلى، أو إذا كنت تخضع للغسيل الكُلوي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لا تقدر على التبوُّل (انقطاع البول).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان مستوى البوتاسيوم أو الصوديوم في الدَّم منخفضًا إلى حد كبير على الرغم من تلقي علاج لزيادة مستويات البوتاسيوم أو الصوديوم في الدَّم لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان مستوى الكالسيوم في الدَّم مرتفعًا إلى حد كبير على الرغم من تلقي علاج لخفض مستويات الكالسيوم في الدَّم لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بمرض النقرس (وجود بلورات من حمض اليوريك في المفاصل).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض شديد بضغط الدَّم (انخفاض ضغط الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك ضيق في الصمام الأورطي (ضيق الصمام الأورطي) أو صدمة قلبية (حالة يكون فيها القلب لديك غير قادر على إمداد الجسم بما يكفي من الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل القلب بعد التَّعرض لنوبة قلبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض السُّكَّري أو تُعاني من قصور بوظائف الكُلى ويتم علاجك بدواء خافض لضغط الدَّم يحتوي على أليسكيرين.</p><p dir="RTL"><strong>إذا كان ينطبق عليك أيٌّ مما سبق، فلا تتناول عقار إكسفورج إتش سي تي، وتحدث إلى طبيبك</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول عقار إكسفورج إتش سي تي</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك انخفاض في مستوى البوتاسيوم أو الماغنسيوم في الدَّم (مع أو بدون أعراض كضعف العضلات أو التقلصات العضلية أو النَّظْم القلبي غير الطبيعي).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك انخفاض في مستوى الصوديوم في دمك (مع أو بدون أعراض كالتعب والارتباك والانتفاض العضلي والتشنجات).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك ارتفاع في مستوى الكالسيوم في دمك (مع أو بدون أعراض كالغثيان والقيء والإمساك وألم المعدة والتبوُّل المتكرر والعطش وضعف العضلات والانتفاض العضلي).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من مشاكل بالكُلى، كنت قد أجريت عملية زرع كُلى، أو إذا تم إخبارك بأنَّ لديك ضيقًا في شرايين الكُلى لديك.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من مشاكل بالكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني أو قد عانيت من قبل من فشل القلب أو مرض بالشريان التاجي، لا سيَّما إذا وُصِف لك تناوُل الجرعة القصوى من عقار إكسفورج إتش سي تي (10 مجم/320 مجم/25 مجم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بنوبة قلبية. يُرجى اتباع تعليمات طبيبك الخاصة بجرعة البدء بعناية. قد يُجري لك طبيبك أيضًا فحصًا لوظائف الكُلى لديك.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا أخبرك طبيبك أن لديك تضيقًا في الصمامات بالقلب لديك (يُسمى &quot;ضيق الصمام الأورطي أو الميترالي&quot;) أو زيادة سُمك عضلة القلب لديك بشكل غير طبيعي (يُسمى &quot;اعتلال عضلة القلب التضخمي الانسدادي&quot;).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من فرط الألدوستيرونية. وهو مرض تصنع فيه الغدد الكظرية كمية أكبر مما يجب من هرمون الألدوستيرون. إذا انطبق عليك ذلك، فلا يُوصى باستخدام عقار إكسفورج إتش سي تي.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من مرض يُسمى الذئبة الحمامية الجهازية (يُعرَف أيضًا باسم &quot;الذئبة&quot; أو &quot;SLE&quot;).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت مصابًا بمرض السُّكَّرِي (ارتفاع مستوى السكر بدمك).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كان لديك مستويات مرتفعة من الكوليسترول أو الدهون الثلاثية في دمك.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تتعرَّض لتفاعلات جلدية مثل الطفح الجلدي بعد التعرُّض لأشعة الشمس.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت قد أُصِبت بتفاعلات حساسية تجاه أدوية أخرى لعلاج ارتفاع ضغط الدَّم أو مُدِرات البول (نوع من الأدوية يُعرَف أيضًا باسم &quot;أقراص الماء&quot;)، لا سيَّما إذا كنت تعاني من الربو والحساسية.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت مصابًا بإعياء (قيء أو إسهال).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت قد عانيت من التَّورم، خاصةً في الوجه والحلق، أثناء تناول الأدوية الأخرى (بما في ذلك مثبطات الأنزيم المُحوِّل للأنجيوتنسين). اذا أصبت بهذه الأعراض، فتوقَّفْ عن تناول عقار إكسفورج إتش سي تي، واتصل بطبيبك على الفور. يجب عليك أَلَّا تتناول عقار إكسفورج إتش سي تي مرة أخرى على الإطلاق.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا تعرَّضت لدوخة و/أو إغماء أثناء العلاج بعقار إكسفورج إتش سي تي، فأخبر طبيبك بأسرع ما يُمكِن.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا تعرَّضت لانخفاض في حدة الرؤية أو ألم بالعين. قد تكون هذه أعراض تراكُم السوائل في الطبقة الوعائية بالعين (انصباب المشيميَّة) أو ارتفاع الضغط بعينك، وقد تُصاب بها في غضون ساعات إلى أسابيع من تناول عقار إكسفورج إتش سي تي يُمكن أن يُؤدي ذلك إلى قصورٍ دائمٍ بالرؤية، إذا لم يُعالج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أيًّا من الأدوية التَّالية التي تُستَخدَم لعلاج ارتفاع ضغط الدَّم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبط الأنْزيم المُحَوِّل للأَنْجيُوتَنْسين (على سبيل المثال: إنالابريل، ليزينوبريل، راميبريل)، لا سيما إذا كنت تُعاني من مشاكل بالكُلى متعلقة بمرض السُّكَّري.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصِبت بسرطان الجلد، أو إذا تعرَّضت لإصابة غير مُتوَقَّعة بالجلد أثناء العلاج. قد يزيد العلاج بهيدروكلوروثيازيد، خاصةً عند استخدام جرعات مرتفعة على المدى الطويل، من خطر الإصابة ببعض أنواع سرطان الجلد والشفة (سرطان الجلد غير الميلانيني). احرص على حماية جلدك من أشعة الشمس والأشعة فوق البنفسجية أثناء تناول عقار إكسفورج إتش سي تي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من مشاكل في التنفس أو الرئة (بما في ذلك التهاب أو سوائل في الرئتين) بعد تناول هيدروكلوروثيازيد في الماضي. إذا كنت تعاني من ضيق شديد في التنفس أو صعوبة في التنفس بعد تناول عقار إكسفورج إتش سي تي، فاطلب العناية الطبية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُجري لك طبيبك فحصًا لوظائف الكُلى وضغط الدَّم وكمية الكهارل (على سبيل المثال: البوتاسيوم) في دمك على فترات منتظمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">انظر أيضًا المعلومات تحت عنوان &quot;لا تتناول عقار إكسفورج إتش سي تي في الحالات التالية&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا انطبق عليك أيٌّ مما سبق، فأخبر طبيبك على الفور</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُوصى باستخدام عقار إكسفورج إتش سي تي من قبل الأطفال والمراهقين تحت سن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبار السن </strong><strong>(65 </strong><strong>سنة فأكبر</strong><strong>)</strong></p><p dir="RTL">من الممكن أن يتم استخدام عقار إكسفورج إتش سي تي من قبل الأشخاص الذين تبلغ أعمارهم 65 عامًا فأكثر بنفس الجرعة المقررة للبالغين وبالطريقة نفسها التي تناولوا بالفعل بها الثلاث مواد التي تسمى أملوديبين، فالسارتان وهيدروكلوروثيازيد. يجب على المرضى من كبار السن، لا سيَّما أولئك الذين يتناولون الجرعة القصوى من عقار إكسفورج إتش سي تي (10 مجم/320 مجم/25 مجم)،التحقق من ضغط الدَّم لديهم بصفة منتظمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وعقار إكسفورج إتش سي تي</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. قد يحتاج طبيبك إلى تغيير جرعتك، و/ أو اتخاذ احتياطات أخرى. في بعض الحالات قد يتعين عليك التَّوقف عن تناول أحد الأدوية. يُعَد هذا مُهِمًّا بشكل خاص إذا كنت تستخدم أيًّا من الأدوية المُدرَجة أدناه:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>لا تتناوله بمصاحبة</u><u>:</u></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (دواء يُستَخدَم لعلاج بعض أنواع الاكتئاب)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية أو المواد التي تزيد من كمية البوتاسيوم في الدَّم لديك. وتتضمن مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم، والأدوية المُوفرة للبوتاسيوم والهيبارين؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُثبطات أنزيم تحويل الأنجيوتنسين أو أليسكيرين (انظر ايضًا المعلومات تحت عنوانَي&quot;لا تتناول عقار إكسفورج إتش سي تي في الحالات التالية&quot; و&quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>يجب توخي الحذر عند الاستخدام مع</u><u>:</u></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكحوليات والحبوب المنومة وأدوية التخدير (الأدوية التي تسمح للمرضى بالخضوع لجراحة وغيرها من الإجراءات)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمانتادين (علاج مضاد لمرض الشلل الرعَّاش &quot;مرض باركنسون&quot; ويُستخدم أيضًا لعلاج بعض الأمراض الناجمة عن الفيروسات أو للوقاية منها)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للفعل الكوليني (أدوية تُستخدم لعلاج اضطراباتٍ مختلفة مثل: تقلصات الجهاز الهضمي، تشنجات المثانة، الربو، دوار الحركة، التشنجات العضلية، مرض الشلل الرعَّاش &quot;مرض باركنسون&quot; وتُستخدم للمساعدة في إخضاعك للتخدير)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للاختلاجات والأدوية الموازنة للحالة المزاجية التي تُستَخدَم لعلاج الصرع والاضطراب ثنائي القطب (على سبيل المثال: كَرْبامازِيبين، فينوباربيتال، فينيتوين، فوسفينيتوين، بريميدون)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كولستيرامين أو كوليستيبول أو غيرهما من الراتنجات (مواد تُستخدم بشكل أساسي لعلاج ارتفاع مستويات الدهون بالدَّم)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيمفاستاتين (دواء يُستخدم للتَّحكم في ارتفاع مستويات الكوليسترول)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (دواء يُستَخدَم في عمليات الزراعة لمنع رفض الجسم للعضو المزروع أو لعلاج حالات أخرى، مثل: التهاب المفاصل الروماتويدي أو التهاب الجلد التَّأَتُّبِيّ)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية السامة للخلايا (تُستَخدَم لعلاج السرطان)، مثل ميثوتريكسات أو سيكلوفوسفاميد؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسِين أو غيره من جليكوزيدات الديجيتاليس (أدوية تُستَخدَم لعلاج مشاكل القلب)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل، ديلتِيازِيم (أدوية للقلب)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائط التبايُن التي تحتوي على اليود (أدوية تُستخدم لفحوصات التصوير)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج مرض السُّكَّرِي (الأدوية التي يتم تناولها عن طريق الفم مثل ميتفورمين أو الأنسولين)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج مرض النقرس، مثل ألوبيورينول؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد ترفع مستويات السُّكَّر في الدَّم (حاصرات بيتا، ديازوكسيد)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تحفز &quot;<em>التفاف النقاط</em>&quot; (عدم انتظام ضربات القلب)، مثل الأدوية المضادة لاضطرابات النظم القلبي (الأدوية التي تُستَخدَم لعلاج مشاكل القلب) وبعض مضادات الذهان؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تقلل من كمية الصوديوم في دمك، مثل مضادات الاكتئاب، مضادات الذهان، مضادات الصرع؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تقلل من كمية البوتاسيوم في دمك، مثل مُدِرات البول (أقراص الماء)، أو الكورتيكوستيرويدات، أو المُليّنات، أو أَمْفُوتيريسين أو البنسلين جي؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لرفع ضغط الدَّم، مثل: الأدرينالين أو النورادرينالين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج فيروس نقص المناعة البشرية/ الإيدز (على سبيل المثال: ريتونافير، إندينافير، نيلفينافير)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج العدوى الفطرية (على سبيل المثال: كيتوكونازول، إتراكونازول)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لعلاج تقرُّح المريء والتهابه (كَرْبينُوكْسُولُون)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم لتخفيف الألم أو الالتهابات، خاصةً مضادات الالتهاب غير الستيرويديةبما في ذلك مثبطات سيكلو أوكسجينيز-2 (COX-2) الانتقائية؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مُرخيات العضلات (أدوية تُستَخدَم لإرخاء العضلات أثناء العمليات الجراحية)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيتروجليسرين وغيره من النترات، أو المواد الأخرى التي تُسمى &quot;موسعات الأوعية الدَّموية&quot;؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعالج ارتفاع ضغط الدم، بما في ذلك ميثيل دوبا؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يُستَخدَم لعلاج السل على سبيل المثال)، إريثروميسين، كلاريثروميسين (مضادات حيوية)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دانترولين (تسريب لعلاج الاختلالات الشَّديدة لدرجة حرارة الجسم)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاكروليموس (يستخدم للتحكم في الاستجابة المناعية لجسمك، مما يمكّن جسمك من قبول العضو المزروع)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيتامين &quot;د&quot; وأملاح الكالسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام عقار إكسفورج إتش سي تي مع الأطعمة والمشروبات والكحوليات</strong></p><p dir="RTL">يجب عدم تناول الجريب فروت وعصير الجريب فروت من قبل الأشخاص الذين وُصِفَ لهم عقار إكسفورج إتش سي تي. وذلك لأنَّ الجريب فروت وعصير الجريب فروت من الممكن أن يُؤديا إلى زيادة في مستويات المادة الفعالة &quot;أملوديبين&quot; بالدَّم، مما قد يُؤدي إلى زيادة غير متوقعة في تأثير عقار إكسفورج إتش سي تي الخافض لضغط الدَّم. تحدَّث إلى طبيبك قبل تناوُل الكحوليات. قد يتسبب شرب الكحوليات في هبوط ضغط دمك بصورة كبيرة و/أو قد يزيد من احتمالية إصابتك بدوخة أو إغماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">يجب عليكِ <strong>إخبار طبيبكِ</strong> إذا كنتِ تعتقدين أنكِ حامل (<u>أو قد تصبحين حاملًا</u>). سينصحكِ طبيبكِ عادةً بالتَّوقُّف عن تناوُل عقار إكسفورج إتش سي تي قبل أن تُصبِحي حاملًا، أَو بِمجرّد أَن تعلمي أنكِ حامل، وسينصحكِ بِتناوُل دواء آخر بدلًا من عقار إكسفورج إتش سي تي. لا يُوصى باستخدام عقار إكسفورج إتش سي تي في مراحل الحمل المبكرة، ويجب ألا يتم تناوُله إذا تجاوز حملكِ الشهر الثالث؛ حيث إنه قد يُسبب أضرارًا خطيرة لطفلكِ إذا تم استخدامه بعد الشهر الثالث من الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL"><strong>أخبري طبيبك</strong> إذا كنتِ تُرضعين طفلكِ طبيعيًّا، <u>أو على وشك البدء في إرضاعه طبيعيًّا</u>. اتضح أن أملوديبين يمرُّ إلى لبن الأم بكميات قليلة. لا يُوصى باستخدام عقار إكسفورج إتش سي تي للأمهات المرضعات، وقد يختار لكِ طبيبكِ علاجًا آخر إذا كنتِ ترغبين في الإرضاع طبيعيًّا، خاصَّة إذا كان طفلكِ حديث الولادة، أو مولودًا مبتسرًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشيري طبيبكِ أو الصيدلي قبل تناوُل أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك هذا الدَّواء تشعر بالدوخة، النعاس، الغثيان أو الإصابة بصداع. إذا واجهت هذه الأعراض، فلا تَقُد المركبات أو تستخدم الأدوات أو الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك إذا لم تكن متأكدًا من كيفية التناوُل. سيُساعدك ذلك في الحصول على أفضل النتائج وخفض مخاطر التعرض للآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة من عقار إكسفورج إتش سي تي هي<strong> قرص واحد</strong> في اليوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الأفضل تناول القرص في الوقت نفسه من كل يوم. الصباح هو أفضل وقت للتَّناوُل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع القرص كاملًا مع كوب من الماء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول عقار إكسفورج إتش سي تي مع الطعام أو بدونه. لا تتناول عقار إكسفورج إتش سي تي مع الجريب فروت أو عصير الجريب فروت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصف لك طبيبك جرعة أعلى أو أقل، وفقًا لكيفية استجابتك للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتجاوز الجرعة الموصوفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من عقار إكسفورج إتش سي تي</strong></p><p dir="RTL">إذا تناولت كمية أكبر مما يجب بطريق الخطأ من عقار إكسفورج إتش سي تي أقراص، فتحدَّث إلى الطبيب فورًا. قد تحتاج إلى عناية طبية. قد يتراكم السائل الزائد في رئتيك (الوذمة الرئوية) مما يسبب ضيقًا في التنفس قد يتطور حتى 24-48 ساعة بعد تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تناوُل عقار إكسفورج إتش سي تي</strong></p><p dir="RTL">إذا أغفلت تناوُل جرعة من هذا الدَّواء فقُمْ بتناولها بمجرد تذكُّرك، ثم قم بتناول الجرعة التالية في الوقت المعتاد. إذا كان قد حان موعد الجرعة التَّالية تقريبًا، فما عليك سوى تناوُل القرص التَّالي في الوقت المُعتاد. <strong>لا</strong> تتناول جرعة مضاعفة (قرصين في وقت واحد) لتعويض قرص أغفلته.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول عقار إكسفورج إتش سي تي</strong></p><p dir="RTL">قد يُؤدي إيقاف علاجك بعقار إكسفورج إتش سي تي إلى تفاقم المرض الذي تعاني منه. لا تتوقف عن تناول دوائك ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول هذا الدَّواء دائمًا، حتى إذا كنت تشعر أنك على ما يرام</strong></p><p dir="RTL">في الغالب لا يلاحظ الأشخاص الذين يعانون من ارتفاع ضغط الدَّم أيَّ علامات لهذه المشكلة. قد يشعر الكثيرون بأنهم طبيعيُّون. من المُهِم جدًّا أن تتناول هذا الدَّواء حسب ما يخبرك به طبيبك بالضبط؛ للحصول على أفضل النتائج وتقليل احتمالية التعرُّض لآثار جانبية. حافظ على مواعيدك مع الطبيب حتى إذا كنت تشعر بأن حالتك الصحية على ما يرام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية عن استخدام هذا الدَّواء، فاستشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال في أي تركيبة من ثلاث مواد فعَّالة، لا يُمكِن استبعاد الآثار الجانبية المُرتبطة بكل مُكوِّن فردي. الآثار الجانبية التي جرى الإبلاغ عن حدوثها مع عقار إكسفورج إتش سي تي أو أحد المواد الفعَّالة الثلاث الموجودة به (أملوديبين وفالسارتان وهيدروكلوروثيازيد) مُدرَجة أدناه، وقد تحدث مع استخدام عقار إكسفورج إتش سي تي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض الآثار الجانبية قد تكون خطيرة، وتحتاج إلى عناية طبية فورية</strong><strong>.</strong></p><p dir="RTL"><strong>استشر طبيبًا فورًا إذا تعرضت للإصابة بأي من الآثار الجانبية الخطيرة التَّالية بعد تناول هذا الدَّواء</strong><strong>:</strong></p><p dir="RTL"><em>شائعة </em><em>(</em>قد<em> </em>تُؤثر<em> </em>على<em> </em>ما<em> </em>يصل<em> </em>إلى<em> </em>شخص<em> </em>واحد<em> </em>من<em> </em>كل<em> </em>١٠<em>&nbsp;</em>أشخاص<em>):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم (شعور بالإغماء، شعور بخفة الرأس، فقدان الوعي المفاجئ)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غير شائعة </em><em>(</em><em>قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠ شخص</em><em>):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد في ناتج البول (انخفاض كفاءة وظائف الكُلى).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>نادرة </em><em>(</em><em>قد تُؤثر في ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص</em><em>):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف تلقائي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب بالكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>نادرة جدًّا </em><em>(</em><em>قد تُؤثر في ما يصل إلى شخص واحد من بين كل ١٠٠٠٠ شخص</em><em>):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز مفاجئ بالصدر، ألم الصدر، ضيق بالتَّنفس أو صعوبة في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجفون أو الوجه أو الشفتين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اللسان والحلق مما يسبب صعوبة بالغة في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة بما في ذلك طفح جلدي مكثف، شرى (أرتكاريا)، احمرار الجلد على الجسم بالكامل، حكة شديدة، بثور، تقشر وتورم بالجلد، التهاب الأغشية المخاطية (متلازمة ستيفنز جونسون، انحلال البشرة النخري التَّسَمُّمِيّ) أو غيرها من تفاعلات الحساسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضائقة التنفسية الحادة (تشمل العلامات ضيق التنفس الشديد والحمى والضعف والارتباك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس الذي قد يُسبب ألمًا شديدًا في البطن وألم الظهر المصحوب بشعور شديد بأنك لست على ما يُرام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف وكدمات وحُمّى وعدوى متكررة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبُّس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تشمل الآثار الجانبية الأخرى</strong><strong>:</strong></p><p dir="RTL"><em>شائعة جدًّا</em><em> (</em><em>قد تُؤثر على أكثر من شخص واحد من بين كل </em><em>10&nbsp;</em><em>أشخاص</em><em>):</em></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>انخفاض مستويات البوتاسيوم بالدم</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>ارتفاع مستوى الدهون بالدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>شائعة </em><em>(</em><em>قد تُؤثر على ما يصل إلى شخص واحد من كل ١٠</em><em>&nbsp;</em><em>أشخاص</em><em>):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيمومة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خَفَقان (الشعور بضربات قلبك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم الكاحل (وذمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بعدم الراحة في المعدة بعد تناوُل الوجبات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التبوُّل المتكرر</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>ارتفاع مستوى حمض اليوريك بالدم.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>انخفاض مستويات الماغنسيوم بالدم</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>انخفاض مستويات الصوديوم بالدم</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>دوخة، إغماء عند الوقوف.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>انخفاض الشَّهية</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>غثيان وقيء.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>طفح جلدي مصحوب بحكة وأنواع أخرى من الطفح الجلدي.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>عدم القدرة على تحقيق الانتصاب أو الحفاظ عليه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>غير شائعة </em><em>(</em><em>قد تُؤثر على ما يصل إلى شخص واحد من بين كل ١٠٠ شخص</em><em>):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوران</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب بالرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق بالمعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى النيتروجين يوريا والكرياتينين وحمض اليوريك في الدَّم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الكالسيوم أو الدهون أو الصوديوم في الدَّم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نَفَس له رائحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إِسْهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفَم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب حاسة التذوُّق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الظهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات عضلية/ ضعف/ ألم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالأطراف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على أيٍّ من الوقوف أو المشي بشكل طبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل بتنسيق الحركة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة عند الوقوف أو بعد ممارسة التمارين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الطاقة (خمول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النَّوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو تنميل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال الأعصاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي المفاجئ والمؤقت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم عند الوقوف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسْر التَّنَفُّس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيُّج الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط التعرُّق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم واحمرار وألم على طول الوريد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات الحالة المزاجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم (أرق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بحاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الإحساس بالألم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بصرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور البصر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين بالأذن،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطس/سيلان الأنف نتيجة التهاب بطانة الأنف (التهاب الأنف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في طبيعة الأمعاء المعتادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة بالجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّر لون الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في التبوُّل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الحاجة إلى التبوُّل ليلًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة عدد مرات التبوُّل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بعدم الراحة أو تضخُّم الثديين لدى الرجال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الوزن</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>نادرة </em><em>(</em><em>قد تُؤثر في ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص</em><em>):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الصفائح الدموية بالدَّم (أحيانًا مع حدوث نزيف أو الإصابة بكدمات أسفل الجلد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود سكر بالبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات السُّكَّرِ في الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم الحالة الاستقلابية لمرض السُّكَّرِي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توعك بالبطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الكبد التي قد تحدث مصحوبةً باصفرار لون الجلد والعينين، أو بول داكن اللون(فقر الدَّم الانحلالي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية الجلد تجاه أشعة الشمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع أرجوانية على الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الكُلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>نادرة جدًّا </em><em>(</em><em>قد تُؤثر في ما يصل إلى شخص واحد من بين كل ١٠٠٠٠ شخص</em><em>):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدَّم البيضاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في تعداد الصفائح الدَّموية الذي قد يُؤدي إلى تكدُّم غير معتاد أو سهولة حدوث نزيف (تلف خلايا الدَّم الحمراء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم اللثة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ البطن (التهاب المعدة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد (يرقان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع قيم أنزيمات الكبد، وهو ما قد يؤثر على بعض نتائج الاختبارات الطبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التوتر العضلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدَّموية المصحوب غالبًا بطفح جلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية تجاه الضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات التي تجمع بين التصلب والارتعاش و/أو اضطرابات الحركة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمّى، التهاب الحلق أو قُرَح بالفم، الإصابة بعدوى على نحو أكثر تكرارًا (علامات على نقص أو انخفاض مستوى خلايا الدَّم البيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شحوب الجلد، تعب، عُسْر التَّنَفُّس، بول داكن (فقر الدَّم الانحلالي، تكسير غير طبيعي لخلايا الدَّم الحمراء سواء في الأوعية الدَّموية أو في مكان آخر بالجسم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك، تعب، انتفاض عضلي وتشنجات، التنفس بشكل سريع (قلاء ناتج عن انخفاض الكلوريد بالدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجع شديد بالجزء العلوي من البطن (التهاب البنكرياس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة بالتنفس مصحوبة بحُمى، سعال، أزيز بالصدر، عُسْر التَّنَفُّس (ضيق التنفس، وذمة رئوية، التهاب رئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بالوجه، ألم بالمفاصل، اضطراب عضلي، حُمى (الذئبة الحمامية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية مع أعراض مثل: الطفح الجلدي، بقع حمراء أرجوانية، حُمّى(التهاب الأوعية الدموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض جلدي شديد يسبب طفحًا جلديًّا، احمرار الجلد، ظهور بثور على الشفتين أو العينين أو الفم، تقشُّر الجلد، حُمى (انحلال البشرة النخري التَّسَمُّمِيّ)</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>غير معروفة </em><em>(</em><em>لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</em><em>):</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في نتائج اختبارات الدَّم الخاصة بوظائف الكُلى، ارتفاع مستوى البوتاسيوم في الدَّم، انخفاض مستوى خلايا الدَّم الحمراء</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>نتائج غير طبيعية لاختبار خلايا الدَّم الحمراء</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>انخفاض مستويات أحد أنواع خلايا الدَّم البيضاء والصفائح الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الكرياتينين في الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية باختبارات وظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد في ناتج البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدَّموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف وكدمات وعدوى متكررة (فقر الدم اللاتنسجي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حدة الرؤية أو ألم بعينيك ناجم عن ارتفاع الضغط (علامات محتملة على الإصابة بتراكم السوائل في الطبقة الوعائية بالعين (انصباب المشيميَّة) أو الزَّرَق الحاد ضيق الزاوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عُسْر التَّنَفُّس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد في ناتج البول (علامات محتملة على الإصابة باضطراب كُلوي أو فشل كُلوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض جلدي شديد يسبب طفحًا جلديًّا، احمرار الجلد، ظهور بثور على الشفتين أو العينين أو الفم، تقشُّر الجلد، حُمى (احمرار متعدد الأشكال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات عضلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمى (ارتفاع درجة الحرارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثور بالجلد (علامة على الإصابة بحالة تُسمى التهاب الجلد الفقاعي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد والشفة (سرطان الجلد غير الميلانيني)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة والشريط بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُخزَّن في درجة حرارة تتعدى 30 درجة مئوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب التخزين في العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم أي عبوة تالفة لعقار إكسفورج إتش سي تي أو يظهر عليها علامات العبث.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>إكسفورج إتش سي تي </strong><strong>5 </strong><strong>مجم</strong><strong>/ 160 </strong><strong>مجم</strong><strong>/ 12.5 </strong><strong>مجم أقراص مغلَّفة</strong></p><p dir="RTL">المواد الفعالة لعقار إكسفورج إتش سي تي هي أملوديبين (في هيئة أملوديبين بيزيلات) وفالسارتان وهيدروكلوروثيازيد. تحتوي كل من الأقراص المغلَّفة على 5 مجم أملوديبين (في هيئة أملوديبين بيزيلات)، و160 مجم فالسارتان، و12.5 مجم هيدروكلوروثيازيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: سليلوز دقيق التبلور، كروسبوفيدون نوع أ، سيليكا غروية لامائية، ستيرات الماغنسيوم، هيبروميلوز (استبدال من النوع 2910 (3 مللي باسكال ثانية))، ماكروجول 4000، تلك، ثاني أكسيد التيتانيوم (E171).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إكسفورج إتش سي تي </strong><strong>10 </strong><strong>مجم</strong><strong>/ 160 </strong><strong>مجم</strong><strong>/ 12.5 </strong><strong>مجم أقراص مغلَّفة</strong></p><p dir="RTL">المواد الفعالة لعقار إكسفورج إتش سي تي هي أملوديبين (في هيئة أملوديبين بيزيلات) وفالسارتان وهيدروكلوروثيازيد. تحتوي &nbsp;كلٌّ من الأقراص المغلَّفة على 10 مجم أملوديبين (في هيئة أملوديبين بيزيلات)، 160 مجم فالسارتان و12.5 مجم هيدروكلوروثيازيد</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: سليلوز دقيق التبلور، كروسبوفيدون نوع أ، سيليكا غروية لامائية، ستيرات الماغنسيوم، هيبروميلوز (استبدال من النوع 2910 (3 مللي باسكال ثانية))، ماكروجول 4000، تلك، ثاني أكسيد التيتانيوم (E171)، أكسيد الحديد الأصفر (E172)، أكسيد الحديد الأحمر (E172).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إكسفورج إتش سي تي </strong><strong>5 </strong><strong>مجم</strong><strong>/ 160 </strong><strong>مجم</strong><strong>/ 25 </strong><strong>مجم أقراص مغلَّفة</strong></p><p dir="RTL">المواد الفعالة لعقار إكسفورج إتش سي تي هي أملوديبين (في هيئة أملوديبين بيزيلات) وفالسارتان وهيدروكلوروثيازيد. تحتوي كلٌّ من الأقراص المغلَّفة على 5 مجم أملوديبين (في هيئة أملوديبين بيزيلات)، و160 مجم فالسارتان، و25 مجم هيدروكلوروثيازيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: سليلوز دقيق التبلور، كروسبوفيدون نوع أ، سيليكا غروية لامائية، ستيرات الماغنسيوم، هيبروميلوز (استبدال من النوع 2910 (3 مللي باسكال ثانية))، ماكروجول 4000، تلك، ثاني أكسيد التيتانيوم (E171)، أكسيد الحديد الأصفر (E172).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إكسفورج إتش سي تي </strong><strong>10 </strong><strong>مجم</strong><strong>/ 160 </strong><strong>مجم</strong><strong>/ 25 </strong><strong>مجم أقراص مغلَّفة</strong></p><p dir="RTL">المواد الفعالة لعقار إكسفورج إتش سي تي هي أملوديبين (في هيئة أملوديبين بيزيلات) وفالسارتان وهيدروكلوروثيازيد. تحتوي كل من الأقراص المغلَّفة على 10 مجم أملوديبين (في هيئة أملوديبين بيزيلات)، و160 مجم فالسارتان، و25 مجم هيدروكلوروثيازيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: سليلوز دقيق التبلور، كروسبوفيدون نوع أ، سيليكا غروية لا مائية، ستيرات الماغنسيوم، هيبروميلوز (استبدال من النوع 2910 (3 مللي باسكال ثانية))، ماكروجول 4000، تلك، أكسيد الحديد الأصفر (E172).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إكسفورج إتش سي تي </strong><strong>10 </strong><strong>مجم</strong><strong>/ 320 </strong><strong>مجم</strong><strong>/ 25 </strong><strong>مجم أقراص مغلفة</strong></p><p dir="RTL">المواد الفعالة لعقار إكسفورج إتش سي تي هي أملوديبين (في هيئة أملوديبين بيزيلات) وفالسارتان وهيدروكلوروثيازيد. تحتوي كلٌّ من الأقراص المغلَّفة على 10 مجم أملوديبين (في هيئة أملوديبين بيزيلات)، و320 مجم فالسارتان، و25 مجم هيدروكلوروثيازيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: سليلوز دقيق التبلور، كروسبوفيدون نوع أ، سيليكا غروية لامائية، ستيرات الماغنسيوم، هيبروميلوز (استبدال من النوع 2910 (3 مللي باسكال ثانية))، ماكروجول 4000، تلك، أكسيد الحديد الأصفر (E172).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار إكسفورج إتش سي تي 5 مجم/ 160 مجم/ 12.5 مجم أقراص مغلَّفة هو عبارة عن أقراص بيضاء اللون، بيضوية الشكل، على أحد وجهيها &quot;NVR&quot; وعلى الوجه الآخر &quot;VCL&quot;. الحجم التَّقريبي للقرص: 15 مللي مترًا (الطول) &times; 5.9 مللي متر (العرض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار إكسفورج إتش سي تي 10 مجم/ 160 مجم/ 12.5 مجم أقراص مغلَّفة هو عبارة عن أقراص ذات لون أصفر شاحب، بيضوية الشكل، على أحد وجهيها &quot;NVR&quot; وعلى الوجه الآخر &quot;VDL&quot;. الحجم التَّقريبي للقرص: 15 مللي مترًا (الطول) &times; 5.9 مللي متر (العرض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار إكسفورج إتش سي تي 5 مجم/ 160 مجم/ 25 مجم أقراص مغلَّفة هو عبارة عن أقراص صفراء اللون، بيضوية الشكل، على أحد وجهيها &quot;NVR&quot; وعلى الوجه الآخر &quot;VEL&quot;. الحجم التَّقريبي للقرص: 15 مللي مترًا (الطول) &times; 5.9 مللي متر (العرض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار إكسفورج إتش سي تي 10 مجم/ 160 مجم/ 25 مجم أقراص مغلَّفة هو عبارة عن أقراص ذات لون أصفر مائل إلى البني، بيضوية الشكل، على أحد وجهيها &quot;NVR&quot; وعلى الوجه الآخر &quot;VHL&quot;. الحجم التَّقريبي للقرص: 15 مللي مترًا (الطول) &times; 5.9 مللي متر (العرض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار إكسفورج إتش سي تي 10 مجم/ 320 مجم/ 25 مجم أقراص مغلَّفة هو عبارة عن أقراص ذات لون أصفر مائل إلى البني، بيضوية الشكل، على أحد وجهيها &quot;NVR&quot; وعلى الوجه الآخر &quot;VFL&quot;. الحجم التَّقريبي للقرص: 19 مللي مترًا (الطول) &times; 7.5 مللي متر (العرض).</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار إكسفورج إتش سي تي متوفر في عبوات تحتوي على 14 أو 28 أو 30 أو 56 أو 90 أو 98 أو 280 قرصًا مغلفًا، وفي عبوات متعددة بها 280 قرصًا (تتكون من 4 كرتونات، كل منها يحتوي على 70 قرصًا، أو 20 كرتونة، كل منها يحتوي على 14 قرصًا)، وفي عبوات مستشفيات تحتوي على 56 أو 98 أو 280 قرصًا في شرائط جرعات واحدة مثقوبة.</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في بلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم آخر اعتماد لهذه النَّشرة من قِبَل منظمة الأدوية الأوروبية في 01/2024

ج. للإبلاغ عن أي(ة) أثر/ آثار جانبي(ة): 
•	المملكة العربية السعودية: 

- المركز الوطني للتيقظ والسلامة الدوائية (NPC)
•	مركز اتصال الهيئة السعودية للغذاء والدواء: 19999
•	البريد الالكتروني: npc.drug@sfda.gov.sa
•	الموقع الالكتروني: https://ade.sfda.gov.sa

-	شركة نوفارتس - السعودية - قسم سلامة المرضى:
•	الهاتف المجاني: 8001240078
•	الهاتف:  +966112658100
•	الفاكس: +966112658107
•	البريد الالكتروني: adverse.events@novartis.com

•	دول مجلس التَّعاون الخليجي الأخرى: 
- يُرجى الاتصال بسلطات الاختصاص المعنية

ح.  للإبلاغ عن أي شكوى:  complaints.ksa@novartis.com

إن هذا الدواء
-	الدَّواء مستحضر يُؤثر على صحتك واستهلاكه خلافًا للتَّعليمات يعرضك للخطر. 
-	اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك
-	إن الطبيب والصيدلي هما الخبيران في الدواء وبنفعه و ضرره.
-	لا تقطع مدة العلاج المحددة لك من تلقاء نفسك 
-	لا تكرر صرف الدواء بدون استشارة الطبيب.
-	لا تترك الأدوية في مُتناوَل أيدي الأطفال.


                                                                 مجلس وزراء الصحة العرب
                                                                 اتحاد الصيادلة العرب

خ.	تم اعتماد نشرة معلومات المريض هذه من قبل الهيئة السعودية العامة للغذاء والدَّواء.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets
Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets
Exforge HCT 5 mg/160 mg/25 mg film-coated tablets
Exforge HCT 10 mg/160 mg/25 mg film-coated tablets
Exforge HCT 10 mg/320 mg/25 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets

Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 12.5 mg of hydrochlorothiazide.

Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets

Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 12.5 mg of hydrochlorothiazide.

Exforge HCT 5 mg/160 mg/25 mg film-coated tablets

Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 25 mg of hydrochlorothiazide.

Exforge HCT 10 mg/160 mg/25 mg film-coated tablets

Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 160 mg of valsartan, and 25 mg of hydrochlorothiazide.

Exforge HCT 10 mg/320 mg/25 mg film-coated tablets

Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besylate), 320 mg of valsartan and 25 mg of hydrochlorothiazide.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet)

Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets

White, ovaloid, biconvex tablets with bevelled edge, debossed “NVR” on one side and “VCL” on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets

Pale yellow, ovaloid, biconvex tablets with bevelled edge, debossed “NVR” on one side and “VDL” on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

Exforge HCT 5 mg/160 mg/25 mg film-coated tablets

Yellow, ovaloid, biconvex tablets with bevelled edge, debossed “NVR” on one side and “VEL” on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

Exforge HCT 10 mg/160 mg/25 mg film-coated tablets

Brown-yellow, ovaloid, biconvex tablets with bevelled edge, debossed “NVR” on one side and “VHL” on the other side. Approximate size: 15 mm (length) x 5.9 mm (width).

Exforge HCT 10 mg/320 mg/25 mg film-coated tablets

Brown-yellow, ovaloid, biconvex tablets with bevelled edge, debossed “NVR” on one side and “VFL” on the other side. Approximate size: 19 mm (length) x 7.5 mm (width).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose of Exforge HCT is one tablet per day, to be taken preferably in the morning.</p><p>&nbsp;</p><p>Before switching to Exforge HCT patients should be controlled on stable doses of the monocomponents taken at the same time. The dose of Exforge HCT should be based on the doses of the individual components of the combination at the time of switching.</p><p>&nbsp;</p><p>The maximum recommended dose of Exforge HCT is 10&nbsp;mg/320&nbsp;mg/25&nbsp;mg.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Renal impairment</em></p><p>Due to the hydrochlorothiazide component, Exforge HCT is contraindicated for use in patients with anuria (see section&nbsp;4.3) and in patients with severe renal impairment (glomerular filtration rate (GFR) &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>) (see sections&nbsp;4.3, 4.4 and 5.2).</p><p>&nbsp;</p><p>No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections&nbsp;4.4 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Due to the valsartan component, Exforge HCT is contraindicated in patients with severe hepatic impairment (see section&nbsp;4.3). In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80&nbsp;mg valsartan and therefore Exforge HCT is not suitable in this group of patients (see sections&nbsp;4.3, 4.4 and 5.2). Amlodipine dose recommendations have not been established in patients with mild to moderate hepatic impairment. When switching eligible hypertensive patients (see section&nbsp;4.1) with hepatic impairment to Exforge HCT, the lowest available dose of the amlodipine component should be used.</p><p>&nbsp;</p><p><em>Heart failure and coronary artery disease</em></p><p>There is limited experience with the use of Exforge HCT, particulary at the maximum dose, in patients with heart failure and coronary artery disease. Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Exforge HCT, 10&nbsp;mg/320&nbsp;mg/25&nbsp;mg.</p><p>&nbsp;</p><p><em>Elderly (age 65&nbsp;years or over)</em></p><p>Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Exforge HCT, 10&nbsp;mg/320&nbsp;mg/25&nbsp;mg, since available data in this patient population are limited. When switching eligible elderly hypertensive patients (see section&nbsp;4.1) to Exforge HCT, the lowest available dose of the amlodipine component should be used.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There is no relevant use of Exforge HCT in the paediatric population (patients below age 18&nbsp;years) for the indication of essential hypertension.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oral use.</p><p>Exforge HCT can be taken with or without food.</p><p>The tablets should be swallowed whole with some water, at the same time of the day and preferably in the morning.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substances, to other sulphonamide derivatives, to dihydropyridine derivatives, or to any of the excipients listed in section 6.1.
	Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
	Hepatic impairment, biliary cirrhosis or cholestasis.
	Severe renal impairment (GFR <30 ml/min/1.73 m2), anuria and patients undergoing dialysis.
	Concomitant use of Exforge HCT with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
	Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.
	Severe hypotension.
	Shock (including cardiogenic shock).
	Obstruction of the outflow tract of the left ventricle (e.g. hypertrophic obstructive cardiomyopathy and high grade aortic stenosis).
	Haemodynamically unstable heart failure after acute myocardial infarction.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety and efficacy of amlodipine in hypertensive crisis have not been established.</p><p>&nbsp;</p><p><u>Sodium- and/or volume-depleted patients</u></p><p>&nbsp;</p><p>Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with the maximum dose of Exforge HCT (10&nbsp;mg/320&nbsp;mg/25&nbsp;mg) compared to 1.8% of valsartan/hydrochlorothiazide (320&nbsp;mg/25&nbsp;mg) patients, 0.4% of amlodipine/valsartan (10&nbsp;mg/320&nbsp;mg) patients, and 0.2% of hydrochlorothiazide/amlodipine (25&nbsp;mg/10&nbsp;mg) patients in a controlled trial in patients with moderate to severe uncomplicated hypertension.</p><p>&nbsp;</p><p>In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur after initiation of treatment with Exforge HCT. Exforge HCT should be used only after correction of any pre-existing sodium and/or volume depletion.</p><p>&nbsp;</p><p>If excessive hypotension occurs with Exforge HCT, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. Treatment can be continued once blood pressure has been stabilised.</p><p>&nbsp;</p><p><u>Serum electrolyte changes</u></p><p>&nbsp;</p><p><em><u>Amlodipine/valsartan/hydrochlorothiazide</u></em></p><p>In the controlled trial of Exforge HCT, the counteracting effects of valsartan 320&nbsp;mg and hydrochlorothiazide 25&nbsp;mg on serum potassium approximately balanced each other in many patients. In other patients, one or the other effect may be dominant. Periodic determinations of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.</p><p>&nbsp;</p><p>Periodic determination of serum electrolytes and potassium in particular should be performed at appropriate intervals to detect possible electrolyte imbalance, especially in patients with other risk factors such as impaired renal function, treatment with other medicinal products or history of prior electrolyte imbalances.</p><p>&nbsp;</p><p><em><u>Valsartan</u></em></p><p>Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.</p><p>&nbsp;</p><p><em><u>Hydrochlorothiazide</u></em></p><p>Treatment with Exforge HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia. Thiazide diuretics can precipitate new onset hypokalaemia or exacerbate pre-existing hypokalaemia. Thiazide diuretics should be administered with caution in patients with conditions involving enhanced potassium loss, for example salt‑losing nephropathies and prerenal (cardiogenic) impairment of kidney function. If hypokalaemia develops during hydrochlorothiazide therapy, Exforge HCT should be discontinued until stable correction of the potassium balance.</p><p>&nbsp;</p><p>Thiazide diuretics can precipitate new onset hyponatraemia and hypochloroaemic alkalosis or exacerbate pre-existing hyponatraemia. Hyponatraemia, accompanied by neurological symptoms (nausea, progressive disorientation, apathy) has been observed. Treatment with hydrochlorothiazide should only be started after correction of pre-existing hyponatraemia. In case severe or rapid hyponatraemia develops during Exforge HCT therapy, the treatment should be discontinued until normalisation of natraemia.</p><p>&nbsp;</p><p>All patients receiving thiazide diuretics should be periodically monitored for imbalances in electrolytes, particularly potassium, sodium and magnesium.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>Thiazide diuretics may precipitate azotaemia in patients with chronic kidney disease. When Exforge HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including potassium), creatinine and uric acid serum levels is recommended. Exforge HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section&nbsp;4.3).</p><p>&nbsp;</p><p>No dose adjustment of Exforge HCT is required for patients with mild to moderate renal impairment (GFR &ge;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup>).</p><p>&nbsp;</p><p><u>Renal artery stenosis</u></p><p>&nbsp;</p><p>Exforge HCT should be used with caution to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney since blood urea and serum creatinine may increase in such patients.</p><p>&nbsp;</p><p><u>Kidney transplantation</u></p><p>&nbsp;</p><p>To date there is no experience of the safe use of Exforge HCT in patients who have had a recent kidney transplantation.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>Valsartan is mostly eliminated unchanged via the bile. The half-life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dose recommendations have not been established. In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80&nbsp;mg valsartan, and therefore, Exforge HCT is not suitable in this group of patients (see sections&nbsp;4.2, 4.3 and 5.2).</p><p>&nbsp;</p><p><u>Angioedema</u></p><p>&nbsp;</p><p>Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue, has been reported in patients treated with valsartan. Some of these patients previously experienced angioedema with other medicinal products including ACE inhibitors. Exforge HCT should be discontinued immediately in patients who develop angioedema and should not be re-administered.</p><p>&nbsp;</p><p><u>Heart failure and coronary artery disease/post-myocardial infarction</u></p><p>&nbsp;</p><p>As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotaemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with valsartan. Evaluation of patients with heart failure or post-myocardial infarction should always include assessment of renal function.</p><p>&nbsp;</p><p>In a long-term, placebo-controlled study (PRAISE-2) of amlodipine in patients with NYHA (New York Heart Association Classification) III and IV heart failure of non-ischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.</p><p>&nbsp;</p><p>Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p>&nbsp;</p><p>Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Exforge HCT, 10&nbsp;mg/320&nbsp;mg/25&nbsp;mg, since available data in these patient populations is limited.</p><p>&nbsp;</p><p><u>Aortic and mitral valve stenosis</u></p><p>&nbsp;</p><p>As with all other vasodilators, special caution is indicated in patients with mitral stenosis or significant aortic stenosis that is not high grade.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections&nbsp;4.3 and 4.6).</p><p>&nbsp;</p><p><u>Primary hyperaldosteronism</u></p><p>&nbsp;</p><p>Patients with primary hyperaldosteronism should not be treated with the angiotensin II antagonist valsartan as their renin-angiotensin system is not activated. Therefore, Exforge HCT is not recommended in this population.</p><p>&nbsp;</p><p><u>Systemic lupus erythematosus</u></p><p>&nbsp;</p><p>Thiazide diuretics, including hydrochlorothiazide, have been reported to exacerbate or activate systemic lupus erythematosus.</p><p>&nbsp;</p><p><u>Other metabolic disturbances</u></p><p>&nbsp;</p><p>Thiazide diuretics, including hydrochlorothiazide, may alter glucose tolerance and raise serum levels of cholesterol, triglycerides and uric acid. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required.</p><p>&nbsp;</p><p>Due to the hydrochlorothiazide component, Exforge HCT is contraindicated in symptomatic hyperuricaemia. Hydrochlorothiazide may raise the serum uric acid level due to reduced clearance of uric acid and may cause or exacerbate hyperuricaemia as well as precipitate gout in susceptible patients.</p><p>&nbsp;</p><p>Thiazides reduce urinary calcium excretion and may cause intermittant and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Exforge HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre-existing hypercalcaemia. Exforge HCT should be discontinued if hypercalcaemia develops during treatment. Serum levels of calcium should be periodically monitored during treatment with thiazides. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p>&nbsp;</p><p><u>Photosensitivity</u></p><p>&nbsp;</p><p>Cases of photosensitivity reactions have been reported with thiazide diuretics (see section&nbsp;4.8). If photosensitivity reaction occurs during treatment with Exforge HCT, it is recommended to stop the treatment. If a readministration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.</p><p><u>&nbsp;</u></p><p><u>Choroidal effusion, acute myopia and secondary acute angle-closure glaucoma</u></p><p>&nbsp;</p><p>Hydrochlorothiazide, a sulphonamide, has been associated with an idiosyncratic reaction resulting in choroidal effusion with visual field defect, acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to a week of treatment initiation. Untreated acute-angle closure glaucoma can lead to permanent vision loss.</p><p>&nbsp;</p><p>The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatment may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulphonamide or penicillin allergy.</p><p>&nbsp;</p><p><u>General</u></p><p>&nbsp;</p><p>Caution should be exercised in patients who have shown prior hypersensitivity to other angiotensin II receptor antagonists. Hypersensitivity reactions to hydrochlorothiazide are more likely in patients with allergy and asthma.</p><p>&nbsp;</p><p><u>Elderly (age 65&nbsp;years or over)</u></p><p>&nbsp;</p><p>Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Exforge HCT, 10&nbsp;mg/320&nbsp;mg/25&nbsp;mg, since available data in this patient population are limited.</p><p>&nbsp;</p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>&nbsp;</p><p>There is evidence that the concomitant use of ACE inhibitors, ARBs or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is therefore not recommended (see sections&nbsp;4.5 and 5.1).</p><p>&nbsp;</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE inhibitors and ARBs should not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p><u>Non-melanoma skin cancer</u></p><p>&nbsp;</p><p>An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry. Photosensitising actions of hydrochlorothiazide could act as a possible mechanism for NMSC.</p><p>&nbsp;</p><p>Patients taking hydrochlorothiazide should be informed of the risk of NMSC and advised to regularly check their skin for any new lesions and promptly report any suspicious skin lesions. Possible preventive measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to the patients in order to minimise the risk of skin cancer. Suspicious skin lesions should be promptly examined potentially including histological examinations of biopsies. The use of hydrochlorothiazide may also need to be reconsidered in patients who have experienced previous NMSC (see also section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Acute respiratory toxicity</u></p><p>&nbsp;</p><p>Very rare severe cases of acute respiratory toxicity, including acute respiratory distress syndrome (ARDS), have been reported after taking hydrochlorothiazide. Pulmonary oedema typically develops within minutes to hours after hydrochlorothiazide intake. At the onset, symptoms include dyspnoea, fever, pulmonary deterioration and hypotension. If diagnosis of ARDS is suspected, Exforge HCT should be withdrawn, and appropriate treatment given. Hydrochlorothiazide should not be administered to patients who previously experienced ARDS following hydrochlorothiazide intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No formal interaction studies with other medicinal products have been performed with Exforge HCT. Thus, only information on interactions with other medicinal products that are known for the individual active substances is provided in this section.</p><p>&nbsp;</p><p>However, it is important to take into account that Exforge HCT may increase the hypotensive effect of other antihypertensive agents.</p><p>&nbsp;</p><p><u>Concomitant use not recommended</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:607px"><tbody><tr><td style="vertical-align:top"><p><strong>Exforge HCT individual component</strong></p></td><td style="vertical-align:top"><p><strong>Known interactions with the following agents</strong></p></td><td style="vertical-align:top"><p><strong>Effect of the interaction with other medicinal products</strong></p></td></tr><tr><td style="vertical-align:top"><p>Valsartan and</p><p>HCT</p></td><td style="vertical-align:top"><p>Lithium</p></td><td><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, angiotensin II receptor antagonists including valsartan or thiazides. Since renal clearance of lithium is reduced by thiazides, the risk of lithium toxicity may presumably be increased further with Exforge HCT. Therefore careful monitoring of serum lithium concentrations is recommended during concomitant use.</p></td></tr><tr><td style="vertical-align:top"><p>Valsartan</p></td><td style="vertical-align:top"><p>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</p></td><td style="vertical-align:top"><p>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, frequent monitoring of potassium plasma levels is advised.</p></td></tr><tr><td style="vertical-align:top"><p>Amlodipine</p></td><td style="vertical-align:top"><p>Grapefruit or grapefruit juice</p></td><td style="vertical-align:top"><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients, resulting in increased blood pressure lowering effects.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Caution required with concomitant use</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:607px"><tbody><tr><td style="vertical-align:top"><p><strong>Exforge HCT individual component</strong></p></td><td style="vertical-align:top"><p><strong>Known interactions with the following agents</strong></p></td><td style="vertical-align:top"><p><strong>Effect of the interaction with other medicinal products</strong></p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Amlodipine</p></td><td style="vertical-align:top"><p><em>CYP3A4 inhibitors</em></p><p>(i.e. ketoconazole, itraconazole, ritonavir)</p></td><td style="vertical-align:top"><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</p></td></tr><tr><td style="vertical-align:top"><p><em>CYP3A4 inducers </em>(anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone], rifampicin, <em>Hypericum perforatum </em>[St. John&rsquo;s wort])</p></td><td style="vertical-align:top"><p>Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine may vary. Therefore, blood pressure should be monitored and dose regulation considered both during and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin, hypericum perforatum).</p></td></tr><tr><td style="vertical-align:top"><p><em>Simvastatin</em></p></td><td style="vertical-align:top"><p>Co-administration of multiple doses of 10&nbsp;mg amlodipine with 80&nbsp;mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose of simvastatin to 20&nbsp;mg daily in patients on amlodipine.</p></td></tr><tr><td style="vertical-align:top"><p><em>Dantrolene (infusion)</em></p></td><td style="vertical-align:top"><p>In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalaemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalaemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p></td></tr><tr><td style="vertical-align:top"><p>Tacrolimus</p></td><td style="vertical-align:top"><p>There is a risk of increased tacrolimus blood levels when co-administered with amlodipine. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.</p></td></tr><tr><td style="vertical-align:top"><p>Valsartan and HCT</p></td><td style="vertical-align:top"><p><em>Non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors), acetylsalicylic acid (&gt;3&nbsp;g/day), and non-selective NSAIDs</em></p></td><td style="vertical-align:top"><p>NSAIDS can attenuate the antihypertensive effect of both angiotensin II antagonists and hydrochlorothiazide when administered simultaneously. Furthermore, concomitant use of Exforge HCT and NSAIDs may lead to worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</p></td></tr><tr><td style="vertical-align:top"><p>Valsartan</p></td><td style="vertical-align:top"><p><em>Inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir)</em></p></td><td style="vertical-align:top"><p>The results of an <em>in vitro</em> study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and of the hepatic efflux transporter MRP2. Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>HCT</p></td><td style="vertical-align:top"><p><em>Alcohol, barbiturates or narcotics</em></p></td><td style="vertical-align:top"><p>Concomitant administration of thiazide diuretics with substances that also have a blood pressure lowering effect (e.g. by reducing sympathetic central nervous system activity or direct vasodilatation) may potentiate orthostatic hypotension.</p></td></tr><tr><td style="vertical-align:top"><p><em>Amantadine</em></p></td><td style="vertical-align:top"><p>Thiazides, including hydrochlorothiazide, may increase the risk of adverse reactions caused by amantadine.</p></td></tr><tr><td style="vertical-align:top"><p><em>Anticholinergic agents and other medicinal products affecting gastric motility</em></p></td><td style="vertical-align:top"><p>The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g. atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. Conversely, it is anticipated that prokinetic substances such as cisapride may decrease the bioavailability of thiazide-type diuretics.</p></td></tr><tr><td style="vertical-align:top"><p><em>Antidiabetic agents </em>(e.g. insulin and oral antidiabetic agents)</p></td><td style="vertical-align:top"><p>Thiazides may alter glucose tolerance.<strong><em> </em></strong>Dose adjustment of the antidiabetic medicinal product may be necessary.</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Metformin</em></p></td><td style="vertical-align:top"><p>Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p></td></tr><tr><td style="vertical-align:top"><p><em>Beta blockers and diazoxide</em></p></td><td style="vertical-align:top"><p>Concomitant use of thiazide diuretics, including hydrochlorothiazide, with beta blockers may increase the risk of hyperglycaemia. Thiazide diuretics, including hydrochlorothiazide, may enhance the hyperglycaemic effect of diazoxide.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Ciclosporin</em></p></td><td style="vertical-align:top"><p>Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type complications.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Cytotoxic agents</em></p></td><td style="vertical-align:top"><p>Thiazides, including hydrochlorothiazide, may reduce the renal excretion of cytotoxic agents (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Digitalis glycosides</em></p></td><td style="vertical-align:top"><p>Thiazide-induced hypokalaemia or hypomagnesaemia may occur as undesirable effects, favouring the onset of digitalis-induced cardiac arrhythmias.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Iodine contrasting agents</em></p></td><td style="vertical-align:top"><p>In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of iodine products. Patients should be re-hydrated before the administration.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Ion exchange resins</em></p></td><td style="vertical-align:top"><p>Absorption of thiazide diuretics, including hydrochlorothiazide, is decreased by cholestyramine or colestipol. This could result in sub-therapeutic effects of thiazide diuretics. However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4&nbsp;hours before or 4‑6&nbsp;hours after the administration of resins would potentially minimise the interaction.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Medicinal products affecting serum potassium level</em></p></td><td style="vertical-align:top"><p>The hypokalaemic effect of hydrochlorothiazide may be increased by concomitant administration of kaliuretic diuretics, corticosteroids, laxatives, adrenocorticotropic hormone (ACTH), amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives or antiarrhythmics. If these medicinal products are to be prescribed with the amlodipine /valsartan /hydrochlorothiazide combination, monitoring of potassium plasma levels is advised.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Medicinal products</em><em> affecting serum sodium level</em></p></td><td style="vertical-align:top"><p>The hyponatraemic effect of diuretics may be intensified by concomitant administration of medicinal products such as antidepressants, antipsychotics, antiepileptics, etc. Caution is indicated in long-term administration of these medicinal products.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Medicinal products that could induce torsades de pointes</em></p></td><td style="vertical-align:top"><p>Due to the risk of hypokalaemia, hydrochlorothiazide should be administered with caution when associated with medicinal products that could induce <em>torsades de pointes</em>, in particular Class Ia and Class III antiarrhythmics and some antipsychotics.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Medicinal products used in the treatment of gout</em> (probenecid, sulfinpyrazone and allopurinol)</p></td><td style="vertical-align:top"><p>Dose adjustment of uricosuric medicinal products may be necessary as hydrochlorothiazide may raise the level of serum uric acid. Increase of dose of probenecid or sulfinpyrazone may be necessary.</p><p>Co-administration of thiazide diuretics, including hydrochlorothiazide, may increase the incidence of hypersensitivity reactions to allopurinol.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Methyldopa</em></p></td><td style="vertical-align:top"><p>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Non-depolarising skeletal muscle relaxants </em>(e.g. tubocurarine)</p></td><td style="vertical-align:top"><p>Thiazides, including hydrochlorothiazide, potentiate the action of curare derivatives.</p></td></tr><tr><td style="vertical-align:top"><p><em>Other anti-hypertensive medicinal products</em></p></td><td style="vertical-align:top"><p>Thiazides potentiate the antihypertensive action of other antihypertensive drugs (e.g. guanethidine, methyldopa, beta‑blockers, vasodilators, calcium channel blockers, ACE inhibitors, ARBs and Direct Renin Inhibitors [DRIs]).</p></td></tr><tr><td style="vertical-align:top"><p><em>Pressor amines</em> (e.g. noradrenaline, adrenaline)</p></td><td style="vertical-align:top"><p>Hydrochlorothiazide may reduce the response to pressor amines such as noradrenaline. The clinical significance of this effect is uncertain and not sufficient to preclude their use.</p></td></tr><tr><td style="vertical-align:top"><p><em>Vitamin D and calcium salts</em></p></td><td style="vertical-align:top"><p>Administration of thiazide diuretics, including hydrochlorothiazide, with vitamin D or with calcium salts may potentiate the rise in serum calcium. Concomitant use of thiazide type diuretics may lead to hypercalcaemia in patients pre-disposed for hypercalcaemia (e.g. hyperparathyroidism, malignancy or vitamin-D-mediated conditions) by increasing tubular calcium reabsorption.</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Dual blockade of the RAAS with ARBs, ACE inhibitors or aliskiren</u></em></p><p>Clinical trial data have shown that dual blockade of the RAAS through the combined use of ACE inhibitors, ARBs or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections&nbsp;4.3, 4.4 and 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p><em><u>Amlodipine</u></em></p><p>The safety of amlodipine in human pregnancy has not been established. In animal studies, reproductive toxicity was observed at high doses (see section&nbsp;5.3). Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.</p><p>&nbsp;</p><p><em><u>Valsartan</u></em></p><p>The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section&nbsp;4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections&nbsp;4.3 and 4.4).</p><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and if appropriate, alternative therapy should be started.</p><p>&nbsp;</p><p>Exposure to AIIRAs therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>&nbsp;</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections&nbsp;4.3 and 4.4).</p><p>&nbsp;</p><p><em><u>Hydrochlorothiazide</u></em></p><p>There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.</p><p>&nbsp;</p><p>Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p>&nbsp;</p><p><em><u>Amlodipine/valsartan/hydrochlorothiazide</u></em></p><p>There is no experience on the use of Exforge HCT in pregnant women. Based on the existing data with the components, the use of Exforge HCT is not recommended during first trimester and contra-indicated during the second and third trimester of pregnancy (see sections&nbsp;4.3 and 4.4).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3‑7%, with a maximum of 15%. The effect of amlodipine on infants is unknown. No information is available regarding the use of valsartan during breast-feeding. Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit milk production. The use of Exforge HCT during breast-feeding is not recommended. If Exforge HCT is used during breast-feeding, doses should be kept as low as possible. Alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no clinical studies on fertility with Exforge HCT.</p><p>&nbsp;</p><p><em><u>Valsartan</u></em></p><p>Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200&nbsp;mg/kg/day. This dose is 6&nbsp;times the maximum recommended human dose on a mg/m<sup>2</sup> basis (calculations assume an oral dose of 320&nbsp;mg/day and a 60-kg patient).</p><p>&nbsp;</p><p><em><u>Amlodipine</u></em></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients taking Exforge HCT and driving vehicles or using machines should take into account that dizziness or weariness may occasionally occur.</p><p>&nbsp;</p><p>Amlodipine can have mild or moderate influence on the ability to drive and use machines. If patients taking Exforge HCT suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety profile of Exforge HCT presented below is based on clinical studies performed with Exforge HCT and the known safety profile of the individual components amlodipine, valsartan and hydrochlorothiazide.</p><p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety of Exforge HCT has been evaluated at its maximum dose of 10&nbsp;mg/320&nbsp;mg/25&nbsp;mg in one controlled short-term (8&nbsp;weeks) clinical study with 2,271&nbsp;patients, 582 of whom received valsartan in combination with amlodipine and hydrochlorothiazide. Adverse reactions were generally mild and transient in nature and only infrequently required discontinuation of therapy. In this active controlled clinical trial, the most common reasons for discontinuation of therapy with Exforge HCT were dizziness and hypotension (0.7%).</p><p>&nbsp;</p><p>In the 8-week controlled clinical study, no significant new or unexpected adverse reactions were observed with triple therapy treatment compared to the known effects of the monotherapy or dual therapy components.</p><p>&nbsp;</p><p>In the 8-week controlled clinical study, changes in laboratory parameters observed with the combination of Exforge HCT were minor and consistent with the pharmacological mechanism of action of the monotherapy agents. The presence of valsartan in the triple combination attenuated the hypokalaemic effect of hydrochlorothiazide.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Exforge HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually.</p><p>Very common: &ge;1/10; common: &ge;1/100 to &lt;1/10; uncommon: &ge;1/1,000 to &lt;1/100; rare: &ge;1/10,000 to &lt;1/1,000; very rare: &lt;1/10,000, not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:646px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Exforge HCT</strong></p></td><td style="vertical-align:top"><p><strong>Amlodipine</strong></p></td><td style="vertical-align:top"><p><strong>Valsartan</strong></p></td><td style="vertical-align:top"><p><strong>HCT</strong></p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="vertical-align:top"><p>Non-melanoma skin cancer (Basal cell carcinoma and Squamous cell carcinoma)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Agranulocytosis, bone marrow failure</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin and haematocrit decreased</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia, sometimes with purpura</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Aplastic anaemia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p><s>--</s></p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Hyperlipidaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemic alkalosis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatraemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Worsening of diabetic metabolic state</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia/sleep disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Mood swings</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Confusion</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td rowspan="14" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Coordination abnormal</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness postural, dizziness exertional</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Extrapyramidal syndrome</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypertonia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Lethargy</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral neuropathy, neuropathy</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Hypoesthesia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Acute angle-closure glaucoma</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Visual disturbance</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Visual impairment</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Choroidal effusion</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not Known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmias (including bradycardia, ventricular tachycardia, and atrial fibrillation)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Phlebitis, thrombophlebitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Vasculitis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Acute respiratory distress syndrome (ARDS) (see section&nbsp;4.4)</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory distress, pulmonary oedema, pneumonitis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Throat irritation</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td rowspan="13" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal discomfort, abdominal pain upper</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Breath odour</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Change of bowel habit</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Gastritis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Gingival hyperplasia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Liver function test abnormal, including blood bilirubin increase</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare**</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Intrahepatic cholestasis, jaundice</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="17" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Angioedema</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Dermatitis bullous</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Erythema multiforme</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Exanthema</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Photosensitivity reaction*</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Purpura</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Skin discoloration</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria and other forms of rash</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vasculitis necrotising and toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Exfoliative dermatitis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson syndrome</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Quincke oedema</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Joint swelling</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasm</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Muscular weakness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Ankle swelling</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Micturition disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nocturia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Pollakiuria</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal dysfunction</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Renal failure and impairment</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Impotence</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Abasia, gait disturbance</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Discomfort, malaise</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Non cardiac chest pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Lipids increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Blood urea nitrogen increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Blood uric acid increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Glycosuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Blood potassium decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Blood potassium increased</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Weight increase</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p>Weight decrease</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr></tbody></table><p>&nbsp;</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See section&nbsp;4.4 Photosensitivity</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mostly consistent with cholestasis</p><p><em>&nbsp;</em></p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p>Non-melanoma skin cancer: based on available data from epidemiological studies, cumulative dose‑dependent association between hydrochlorothiazide and NMSC has been observed (see also sections&nbsp;4.4 and 5.1).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>--<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>- The National Pharmacovigilance Centre (NPC):</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>--Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><p>-- Please contact the relevant competent authority.</p><p>&nbsp;</p><p><strong>--</strong><strong>To report any complaint(s) :</strong> complaints.ksa@novartis.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>&nbsp;</p><p>There is no experience of overdose with Exforge HCT. The major symptom of overdose with valsartan is possibly pronounced hypotension with dizziness. Overdose with amlodipine may result in excessive peripheral vasodilation and, possibly, reflex tachycardia. Marked and potentially prolonged systemic hypotension, including shock with fatal outcome, have been reported with amlodipine.</p><p>&nbsp;</p><p>Non-cardiogenic pulmonary oedema has rarely been reported as a consequence of amlodipine overdose that may manifest with a delayed onset (24-48&nbsp;hours post-ingestion) and require ventilatory support. Early resuscitative measures (including fluid overload) to maintain perfusion and cardiac output may be precipitating factors.</p><p>&nbsp;</p><p><u>Treatment</u></p><p>&nbsp;</p><p><em><u>Amlodipine/Valsartan/Hydrochlorothiazide</u></em></p><p>Clinically significant hypotension due to Exforge HCT overdose calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output. A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>&nbsp;</p><p><em><u>Amlodipine</u></em></p><p>If ingestion is recent, induction of vomiting or gastric lavage may be considered. Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine has been shown to significantly decrease amlodipine absorption.</p><p>Amlodipine is unlikely to be removed by haemodialysis.</p><p>&nbsp;</p><p><em><u>Valsartan</u></em></p><p>Valsartan is unlikely to be removed by haemodialysis.</p><p>&nbsp;</p><p><em><u>Hydrochlorothiazide</u></em></p><p>Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and hypovolaemia resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms and or accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain anti‑arrhythmic medicinal products.</p><p>The degree to which hydrochlorothiazide is removed by haemodialysis has not been established.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II antagonists, other combinations, ATC code:<strong> </strong>C09DX01.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Exforge HCT combines three antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: amlodipine belongs to the calcium antagonist class and valsartan to the angiotensin II antagonist class of medicines and hydrochlorothiazide belongs to the thiazide diuretics class of medicines. The combination of these substances has an additive antihypertensive effect.</p><p>&nbsp;</p><p><u>Amlodipine/Valsartan/Hydrochlorothiazide</u></p><p>&nbsp;</p><p><em><u>Clinical efficacy and safety</u></em></p><p>Exforge HCT was studied in a double-blind, active controlled study in hypertensive patients. A total of 2,271&nbsp;patients with moderate to severe hypertension (mean baseline systolic/diastolic blood pressure was 170/107&nbsp;mmHg) received treatments of amlodipine/valsartan/hydrochlorothiazide 10&nbsp;mg/320&nbsp;mg/25&nbsp;mg, valsartan/hydrochlorothiazide 320&nbsp;mg/25&nbsp;mg, amlodipine/valsartan 10&nbsp;mg/320&nbsp;mg, or hydrochlorothiazide/amlodipine 25&nbsp;mg/10&nbsp;mg. At study initiation patients were assigned lower doses of their treatment combination and were titrated to their full treatment dose by week&nbsp;2.</p><p>&nbsp;</p><p>At week&nbsp;8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7&nbsp;mmHg with Exforge HCT, 32.0/19.7&nbsp;mmHg with valsartan/hydrochlorothiazide, 33.5/21.5&nbsp;mmHg with amlodipine/valsartan, and 31.5/19.5&nbsp;mmHg with amlodipine/hydrochlorothiazide. The triple combination therapy was statistically superior to each of the three dual combination treatments in reduction of diastolic and systolic blood pressures. The reductions in systolic/diastolic blood pressure with Exforge HCT were 7.6/5.0&nbsp;mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3&nbsp;mmHg greater than with amlodipine/valsartan, and 8.2/5.3&nbsp;mmHg greater than with amlodipine/hydrochlorothiazide. The full blood pressure lowering effect was achieved 2&nbsp;weeks after being on their maximal dose of Exforge HCT. Statistically greater proportions of patients achieved blood pressure control (&lt;140/90&nbsp;mmHg) with Exforge HCT (71%) compared to each of the three dual combination therapies (45‑54%) (p&lt;0.0001).</p><p>&nbsp;</p><p>In a subgroup of 283&nbsp;patients focusing on ambulatory blood pressure monitoring, clinically and statistically superior reductions in 24-hour systolic and diastolic blood pressures were observed with the triple combination compared to valsartan/hydrochlorothiazide, valsartan/amlodipine, and hydrochlorothiazide/amlodipine.</p><p>&nbsp;</p><p><u>Amlodipine</u></p><p>&nbsp;</p><p><em><u>Mechanism of action</u></em></p><p>The amlodipine component of Exforge HCT inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle, causing reductions in peripheral vascular resistance and in blood pressure.</p><p>&nbsp;</p><p><em><u>Pharmacodynamic effects</u></em></p><p>Experimental data suggest that amlodipine binds to both dihydropyridine and non-dihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.</p><p>&nbsp;</p><p>Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation, resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.</p><p>&nbsp;</p><p>Plasma concentrations correlate with effect in both young and elderly patients.</p><p>&nbsp;</p><p>In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and increases in glomerular filtration rate and effective renal plasma flow, without change in filtration fraction or proteinuria.</p><p>&nbsp;</p><p>As with other calcium channel blockers, haemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In haemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and humans, even when co-administered with beta blockers to humans.</p><p>&nbsp;</p><p>Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or humans. In clinical studies in which amlodipine was administered in combination with beta blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed.</p><p>&nbsp;</p><p>Amlodipine has been studied in patients with chronic stable angina, vasospastic angina and angiographically documented coronary artery disease.</p><p>&nbsp;</p><p><em><u>Clinical efficacy and safety</u></em></p><p><em>Use in patients with hypertension</em></p><p>A randomised double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) was performed to compare newer therapies: amlodipine 2.5‑10&nbsp;mg/day (calcium channel blocker) or lisinopril 10‑40&nbsp;mg/day (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5‑25&nbsp;mg/day in mild to moderate hypertension.</p><p>&nbsp;</p><p>A total of 33,357&nbsp;hypertensive patients aged 55 or older were randomised and followed for a mean of 4.9&nbsp;years. The patients had at least one additional coronary heart disease risk factor, including: previous myocardial infarction or stroke (&gt;6&nbsp;months prior to enrollment) or documentation of other atherosclerotic cardiovascular disease (overall 51.5%), type 2 diabetes (36.1%), high density lipoprotein - cholesterol &lt;35&nbsp;mg/dl or &lt;0.906&nbsp;mmol/l (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p>&nbsp;</p><p>The primary endpoint was a composite of fatal coronary heart disease or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: risk ratio (RR) 0.98 95% CI (0.90‑1.07) p=0.65. Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% versus 7.7%, RR 1.38, 95% CI [1.25‑1.52] p&lt;0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy RR 0.96 95% CI [0.89‑1.02] p=0.20.</p><p>&nbsp;</p><p><u>Valsartan</u></p><p>&nbsp;</p><p><em><u>Mechanism of action</u></em></p><p>Valsartan is an orally active, potent and specific angiotensin II receptor antagonist. It acts selectively on the receptor subtype AT<sub>1</sub>, which is responsible for the known actions of angiotensin II.</p><p>&nbsp;</p><p><em><u>Clinical efficacy and safety</u></em></p><p>Administration of valsartan to patients with hypertension results in a drop in blood pressure without affecting pulse rate.</p><p>&nbsp;</p><p>In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2&nbsp;hours, and the peak drop in blood pressure is achieved within 4‑6&nbsp;hours. The antihypertensive effect persists over 24&nbsp;hours after administration. During repeated administration, the maximum reduction in blood pressure with any dose is generally attained within 2‑4&nbsp;weeks.</p><p>&nbsp;</p><p><u>Hydrochlorothiazide</u></p><p>&nbsp;</p><p><em><u>Mechanism of action</u></em></p><p>The site of action of thiazide diuretics is primarily in the renal distal convoluted tubule. It has been shown that there is a high-affinity receptor in the renal cortex as the primary binding site for the thiazide diuretic action and inhibition of NaCl transport in the distal convoluted tubule. The mode of action of thiazides is through inhibition of the Na<sup>+</sup>Cl<sup>-</sup> symporter perhaps by competing for the Cl<sup>-</sup> site, thereby affecting electrolyte reabsorption mechanisms: directly increasing sodium and chloride excretion to an approximately equal extent, and indirectly, by this diuretic action, reducing plasma volume, with consequent increases in plasma renin activity, aldosterone secretion and urinary potassium loss, and a decrease in serum potassium.</p><p>&nbsp;</p><p><em><u>Non-melanoma skin cancer</u></em></p><p>Based on available data from epidemiological studies, cumulative dose‑dependent association between hydrochlorothiazide and NMSC has been observed. One study included a population comprised of 71,533&nbsp;cases of BCC and of 8,629&nbsp;cases of SCC matched to 1,430,833 and 172,462 population controls, respectively. High hydrochlorothiazide use (&ge;50000&nbsp;mg cumulative) was associated with an adjusted odds ratio (OR) of 1.29 (95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC. A clear cumulative dose response relationship was observed for both BCC and SCC. Another study showed a possible association between lip cancer (SCC) and exposure to hydrochlorothiazide: 633&nbsp;cases of lip cancer were matched with 63,067 population controls, using a risk-set sampling strategy. A cumulative dose-response relationship was demonstrated with an adjusted OR 2.1 (95% CI: 1.7-2.6) increasing to OR 3.9 (3.0-4.9) for high use (~25000&nbsp;mg) and OR 7.7 (5.7-10.5) for the highest cumulative dose (~100000&nbsp;mg) (see also section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Exforge HCT in all subsets of the paediatric population in essential hypertension (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p><p><u>Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>&nbsp;</p><p>Two large randomised, controlled trials (ONTARGET [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] and VA NEPHRON-D [The Veterans Affairs Nephropathy in Diabetes]) have examined the use of the combination of an ACE inhibitor with an ARB.</p><p>&nbsp;</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type&nbsp;2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type&nbsp;2 diabetes mellitus and diabetic nephropathy.</p><p>&nbsp;</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE inhibitors and ARBs.</p><p>&nbsp;</p><p>ACE inhibitors and ARBs should therefore not be used concomitantly in patients with diabetic nephropathy (see section&nbsp;4.4).</p><p>&nbsp;</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an ARB in patients with type&nbsp;2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Linearity</u></p><p>&nbsp;</p><p>Amlodipine, valsartan and hydrochlorothiazide exhibit linear pharmacokinetics.</p><p>&nbsp;</p><p><u>Amlodipine/valsartan/hydrochlorothiazide</u></p><p>&nbsp;</p><p>Following oral administration of Exforge HCT in normal healthy adults, peak plasma concentrations of amlodipine, valsartan and hydrochlorothiazide are reached in 6‑8&nbsp;hours, 3&nbsp;hours, and 2&nbsp;hours, respectively. The rate and extent of absorption of amlodipine, valsartan and hydrochlorothiazide from Exforge HCT are the same as when administered as individual dosage forms.</p><p>&nbsp;</p><p><u>Amlodipine</u></p><p>&nbsp;</p><p><em><u>Absorption</u></em></p><p>After oral administration of therapeutic doses of amlodipine alone, peak plasma concentrations of amlodipine are reached in 6‑12&nbsp;hours. Absolute bioavailability has been calculated as between 64% and 80%. Amlodipine bioavailability is unaffected by food ingestion.</p><p>&nbsp;</p><p><em><u>Distribution</u></em></p><p>Volume of distribution is approximately 21&nbsp;l/kg.<em> In vitro</em> studies with amlodipine have shown that approximately 97.5% of circulating drug is bound to plasma proteins.</p><p>&nbsp;</p><p><em><u>Biotransformation</u></em></p><p>Amlodipine is extensively (approximately 90%) metabolised in the liver to inactive metabolites.</p><p>&nbsp;</p><p><em><u>Elimination</u></em></p><p>Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of approximately 30 to 50&nbsp;hours. Steady-state plasma levels are reached after continuous administration for 7‑8&nbsp;days. Ten per cent of original amlodipine and 60% of amlodipine metabolites are excreted in urine.</p><p>&nbsp;</p><p><u>Valsartan</u></p><p>&nbsp;</p><p><em><u>Absorption</u></em></p><p>Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2‑4&nbsp;hours. Mean absolute bioavailability is 23%. Food decreases exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C<sub>max</sub>) by about 50%, although from about 8&nbsp;h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.</p><p>&nbsp;</p><p><em><u>Distribution</u></em></p><p>The steady-state volume of distribution of valsartan after intravenous administration is about 17&nbsp;litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94‑97%), mainly serum albumin.</p><p>&nbsp;</p><p><em><u>Biotransformation</u></em></p><p>Valsartan is not transformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the valsartan AUC). This metabolite is pharmacologically inactive.</p><p>&nbsp;</p><p><em><u>Elimination</u></em></p><p>Valsartan shows multiexponential decay kinetics (t<sub>&frac12;&alpha;</sub> &lt;1&nbsp;h and t<sub>&frac12;&szlig;</sub> about 9&nbsp;h). Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2&nbsp;l/h and its renal clearance is 0.62&nbsp;l/h (about 30% of total clearance). The half-life of valsartan is 6&nbsp;hours.</p><p>&nbsp;</p><p><u>Hydrochlorothiazide</u></p><p>&nbsp;</p><p><em><u>Absorption</u></em></p><p>The absorption of hydrochlorothiazide, after an oral dose, is rapid (T<sub>max</sub> about 2&nbsp;hours). The increase in mean AUC is linear and dose proportional in the therapeutic range.</p><p>&nbsp;</p><p>The effect of food on hydrochlorothiazide absorption, if any, has little clinical significance. Absolute bioavailability of hydrochlorothiazide is 70% after oral administration.</p><p>&nbsp;</p><p><em><u>Distribution</u></em></p><p>The apparent volume of distribution is 4‑8&nbsp;l/kg. Circulating hydrochlorothiazide is bound to serum proteins (40‑70%), mainly serum albumin. Hydrochlorothiazide also accumulates in erythrocytes at approximately 3&nbsp;times the level in plasma.</p><p>&nbsp;</p><p><em><u>Biotransformation</u></em></p><p>Hydrochlorothiazide is eliminated predominantly as unchanged compound.</p><p>&nbsp;</p><p><em><u>Elimination</u></em></p><p>Hydrochlorothiazide is eliminated from plasma with a half-life averaging 6 to 15&nbsp;hours in the terminal elimination phase. There is no change in the kinetics of hydrochlorothiazide on repeated dosing, and accumulation is minimal when dosed once daily. More than 95% of the absorbed dose is being excreted as unchanged compound in the urine. The renal clearance is composed of passive filtration and active secretion into the renal tubule.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Paediatric patients (age below 18&nbsp;years)</u></em></p><p>No pharmacokinetic data are available in the paediatric population.</p><p>&nbsp;</p><p><em><u>Elderly (age 65&nbsp;years or over)</u></em></p><p>Time to peak plasma amlodipine concentrations is similar in young and elderly patients. In elderly patients, amlodipine clearance tends to decline, causing increases in the area under the curve (AUC) and elimination half-life. Mean systemic AUC of valsartan is higher by 70% in the elderly than in the young, therefore caution is required when increasing the dosage.</p><p>&nbsp;</p><p>Systemic exposure to valsartan is slightly elevated in the elderly as compared to the young, but this has not been shown to have any clinical significance.</p><p>&nbsp;</p><p>Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly subjects compared to young healthy volunteers.</p><p>&nbsp;</p><p>Since the three components are equally well tolerated in younger and elderly patients, normal dose regimens are recommended (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan.</p><p>&nbsp;</p><p>Patients with mild to moderate renal impairment may therefore receive the usual initial dose (see sections&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p>In the presence of renal impairment, mean peak plasma levels and AUC values of hydrochlorothiazide are increased and the urinary excretion rate is reduced. In patients with mild to moderate renal impairment, a 3-fold increase in hydrochlorothiazide AUC has been observed. In patients with severe renal impairment an 8-fold increase in AUC has been observed. Exforge HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section&nbsp;4.3).</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic impairment have decreased clearance of amlodipine with resulting increase of approximately 40&ndash;60% in AUC. On average, in patients with mild to moderate chronic liver disease, exposure (measured by AUC values) to valsartan is twice that found in healthy volunteers (matched by age, sex and weight). Due to the valsartan component, Exforge HCT is contraindicated in patients with hepatic impairment (see sections&nbsp;4.2 and 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Amlodipine/Valsartan/Hydrochlorothiazide</u></p><p>&nbsp;</p><p>In a variety of preclinical safety studies conducted in several animal species with amlodipine, valsartan, hydrochlorothiazide, valsartan/hydrochlorothiazide, amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide (Exforge HCT), there was no evidence of systemic or target organ toxicity that would adversely affect the development of Exforge HCT for clinical use in humans.</p><p>&nbsp;</p><p>Preclinical safety studies of up to 13&nbsp;weeks in duration were conducted with amlodipine/valsartan/hydrochlorothiazide in rats. The combination resulted in expected reduction of red blood cell mass (erythrocytes, haemoglobin, haematocrit, and reticulocytes), increase in serum urea, increase in serum creatinine, increase in serum potassium, juxtaglomerular (JG) hyperplasia in the kidney and focal erosions in the glandular stomach in rats. All these changes were reversible after a 4-week recovery period and were considered to be exaggerated pharmacological effects.</p><p>&nbsp;</p><p>The amlodipine/valsartan/hydrochlorothiazide combination was not tested for genotoxicity or carcinogenicity as there was no evidence of any interaction between these substances, which have been on the market for a long time. However, amlodipine, valsartan and hydrochlorothiazide have been tested individually for genotoxicity and carcinogenicity with negative results.</p><p>&nbsp;</p><p><u>Amlodipine</u></p><p>&nbsp;</p><p><em><u>Reproductive toxicology</u></em></p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50&nbsp;times greater than the maximum recommended dosage for humans based on mg/kg.</p><p>&nbsp;</p><p><em><u>Impairment of fertility</u></em></p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64&nbsp;days and females 14&nbsp;days prior to mating) at doses up to 10 mg/kg/day (8&nbsp;times* the maximum recommended human dose of 10&nbsp;mg on a mg/m<sup>2</sup> basis). In another rat study in which male rats were treated with amlodipine besilate for 30&nbsp;days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p>&nbsp;</p><p><em><u>Carcinogenesis, mutagenesis</u></em></p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5&nbsp;mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10&nbsp;mg on a mg/m<sup>2</sup> basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>&nbsp;</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>&nbsp;</p><p>* Based on patient weight of 50&nbsp;kg</p><p><em>&nbsp;</em></p><p><u>Valsartan</u></p><p>&nbsp;</p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p><p>&nbsp;</p><p>In rats, maternally toxic doses (600&nbsp;mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section&nbsp;4.6). These doses in rats (600&nbsp;mg/kg/day) are approximately 18&nbsp;times the maximum recommended human dose on a mg/m<sup>2 </sup>basis (calculations assume an oral dose of 320&nbsp;mg/day and a 60-kg patient).</p><p>&nbsp;</p><p>In non-clinical safety studies, high doses of valsartan (200 to 600&nbsp;mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised blood urea nitrogen, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600&nbsp;mg/kg/day) are approximately 6 and 18&nbsp;times the maximum recommended human dose on a mg/m<sup>2</sup> basis (calculations assume an oral dose of 320&nbsp;mg/day and a 60-kg patient).</p><p>&nbsp;</p><p>In marmosets at comparable doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy including raised blood urea nitrogen and creatinine.</p><p>&nbsp;</p><p>Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Exforge HCT 5&nbsp;mg/160&nbsp;mg/12.5&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p><em><u>Tablet core</u></em></p><p>Cellulose microcrystalline</p><p>Crospovidone (type A)</p><p>Silica, colloidal anhydrous</p><p>Magnesium stearate</p><p>&nbsp;</p><p><em><u>Coating</u></em></p><p>Hypromellose, substitution type 2910 (3 mPa.s)</p><p>Titanium dioxide (E171)</p><p>Macrogol 4000</p><p>Talc</p><p>&nbsp;</p><p><u>Exforge HCT 10&nbsp;mg/160&nbsp;mg/12.5&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p><em><u>Tablet core</u></em></p><p>Cellulose microcrystalline</p><p>Crospovidone (type A)</p><p>Silica, colloidal anhydrous</p><p>Magnesium stearate</p><p>&nbsp;</p><p><em><u>Coating</u></em></p><p>Hypromellose, substitution type 2910 (3 mPa.s)</p><p>Macrogol 4000</p><p>Talc</p><p>Titanium dioxide (E171)</p><p>Iron oxide, yellow (E172)</p><p>Iron oxide, red (E172)</p><p>&nbsp;</p><p><u>Exforge HCT 5&nbsp;mg/160&nbsp;mg/25&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p><em><u>Tablet core</u></em></p><p>Cellulose microcrystalline</p><p>Crospovidone (type A)</p><p>Silica, colloidal anhydrous</p><p>Magnesium stearate</p><p>&nbsp;</p><p><em><u>Coating</u></em></p><p>Hypromellose, substitution type 2910 (3 mPa.s)</p><p>Macrogol 4000</p><p>Talc</p><p>Titanium dioxide (E171)</p><p>Iron oxide, yellow (E172)</p><p>&nbsp;</p><p><u>Exforge HCT 10&nbsp;mg/160&nbsp;mg/25&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p><em><u>Tablet core</u></em></p><p>Cellulose microcrystalline</p><p>Crospovidone (type A)</p><p>Silica, colloidal anhydrous</p><p>Magnesium stearate</p><p>&nbsp;</p><p><em><u>Coating</u></em></p><p>Hypromellose, substitution type 2910 (3 mPa.s)</p><p>Macrogol 4000</p><p>Talc</p><p>Iron oxide, yellow (E172)</p><p>&nbsp;</p><p><u>Exforge HCT 10&nbsp;mg/320&nbsp;mg/25&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p><em><u>Tablet core</u></em></p><p>Cellulose microcrystalline</p><p>Crospovidone (type A)</p><p>Silica, colloidal anhydrous</p><p>Magnesium stearate</p><p>&nbsp;</p><p><em><u>Coating</u></em></p><p>Hypromellose, substitution type 2910 (3 mPa.s)</p><p>Macrogol 4000</p><p>Talc</p><p>Iron oxide, yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PVDC blisters. One blister contains 7, 10 or 14&nbsp;film-coated tablets.</p><p>Pack sizes: 14, 28, 30, 56, 90, 98 or 280&nbsp;film-coated tablets.</p><p>Multipacks of 280&nbsp;tablets, comprising 20&nbsp;cartons, each containing 14&nbsp;tablets.</p><p>&nbsp;</p><p>PA/AL/PVC blister pack. One blister contains 7, 10 or 14 film-coated tablets.<br />Pack sizes: 14, 28, 30, 56, 90, 98 or 280 film-coated tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -EMA on 01/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>